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Genital inflammation associated with sexually transmitted infections (STIs) and Bacterial Vaginosis 
(BV) is considered a key driver in the HIV/AIDS epidemic. A new rapid point-of-care (POC) test that 
detects genital inflammation in women was recently developed by researchers at the University of 
Cape Town. The objective of this study was to establish the cost-effectiveness of this novel 
intervention in comparison to other relevant screening and diagnostic strategies for the management 
of STIs and BV in women. It follows prior research on the cost and affordability of national 
implementation of screening with this technology. This research indicated that it might not affordable 
policy option given current health budget constraints.  
A decision analysis model was developed to estimate the cost and health outcomes associated with 
five different screening and diagnostic strategies for women seeking care in the South African public 
health sector. A decision tree was constructed, and all cost and effectiveness parameters were 
obtained from published and unpublished literature. The model incorporated all clinic-level and 
treatment costs associated with diagnosing and treating a single episode of disease.  The main 
outcome measure was the effectiveness of each approach in correctly diagnosing an STI or BV in 
women, proxied by its sensitivity measure. One-way sensitivity analyses and threshold analysis were 
conducted to test key uncertainties and assumptions in the model. 
In the base-case scenario, screening with GIFT and treating GIFT-positive cases based on syndromic 
management guidelines, was the most cost-effective strategy with an ICER of $2.60 per women 
diagnosed with an STI(s) and/or BV. This strategy remained the most cost-effective even when a 
variety of parameters were varied in one-way sensitivity analyses. A threshold analyses on GIFT’s 
sensitivity revealed that the strategy would remain the most cost-effective unless the sensitivity of 
the test assay decreased below 14.83%. 
From the perspective of the South African government, screening with GIFT and treating positive cases 
according to syndromic management guidelines is a highly cost-effective strategy for the management 
of STIs and BV in women in the reproductive age, but affordability considerations cannot be ignored. 
The newly developed rapid POC can significantly improve the management of STIs and BV in women 
through identifying asymptomatic women and at the same time, reducing their risk of HIV infection, 
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Globally, sexually transmitted infections (STIs) and Bacterial Vaginosis (BV) pose a massive, and often 
overlooked, challenge to public health and development. The annual incidence of STIs is exceeded 
only by that of malaria, lower respiratory infections and diarrheal diseases and places substantial 
pressure on health care expenditure and health system at large (Kamb et al., 2008; Torrone et al., 
2018).  In 2012, the World Health Organization (WHO) reported that annually, around 499 million new 
cases of the four most common curable STIs, Chlamydia trachomatis, Neisseria gonorrhoeae, 
Trichomonas vaginalis and Syphilis infections, occurred globally (World Health Organization, 2012). 
Global estimates of BV incidence and prevalence remains extremely limited (Torrone et al., 2018).  
However, reported STIs typically only represent around 50% of all infections. Many infections, 
especially in women, present asymptomatic, regardless of viral or bacterial aetiology (Kamb et al.,  
2008). Kaida et al. (2018) report that this estimated as high as 75%. BV is not classified as an STI but is 
associated with various STIs and is characterized by abnormal vaginal discharge in women in their 
reproductive age (Morris, Rogers and Kinghorn, 2001).  
South Africa houses one of the largest burdens of STIs in the world (Johnson et al., 2007). The high 
prevalence of STIs in developing countries result in significant losses for individual and community 
productivity. Most of these infections are preventable or curable with relatively inexpensive and 
simple interventions. If left untreated, however, it can lead to various serious sexual and reproductive 
complications and increase the risk of HIV acquisition  (Kamb et al., 2008; Masson et al., 2016). STIs 
are considered one of the leading causes of disability adjusted life years lost for women in the 
reproductive age in developing countries (Kamb et al., 2008). 
There is an urgent need for the improvement of STI management in women in resource-constrained 
settings (Masson et al., 2016). The development of rapid point-of-care (POC) tests for STIs has been a 
priority on the global agenda since the 1990s, while syndromic management was originally only 
intended as a temporary solution (Romøren, 2008). The WHO has also developed the ASSURED criteria 
under the Sexually Transmitted Diseases Diagnostics Initiative. This acronym specifies 7 criteria for any 
newly developed diagnostic test in order to ensure that it meets disease control requirements. 
Affordability is one of the key requirements (Peeling et al., 2006). 
Researchers at the Division of Medical Virology at the University of Cape recently developed an 
inexpensive, rapid POC test; the Genital Inflammation Test (GIFT). GIFT detects STIs and BV and 
inflammatory bacteria in the female genital tract with a sensitivity of 77% and a specificity of 71%. The 
device has been validated in a biomarker validation study and is to be rolled out in a cross-sectional 
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validation study to evaluate and optimize its performance. The validation study will be conducted at 
healthcare facilities in Cape Town. 
The purpose of this proposed study is to conduct a cost-effectiveness analysis of different screening 
strategies, for STIs and BV among women in Cape Town and ultimately, the prevention of HIV. 
1.2. Problem Statement  
The persistent public health burden of STIs is the result of various complex and interlinked factors, but 
the delay in treatment resulting from existing diagnostic and treatment protocols is considered a 
major contributor. (Gaydos and Hardick, 2014). STIs and BV that are left untreated or that are treated 
inappropriately, can lead to reproductive complications in women such as infertility and adverse 
pregnancy outcomes (Kamb et al., 2008). STIs and BV, which causes inflammation in the female genital 
tract, are also recognized as key drivers of the HIV/AIDS (Johnson et al., 2012; Mlisana, 2014).  
Inflammation in the female genital tract caused by STIs and BV,  increase the risk of acquiring HIV by 
reducing the effectiveness of the mucosal barrier, recruiting HIV target cells and promoting HIV 
replication (Passmore, Jaspan and Masson, 2016; Masson et al., 2014). BV infection increases a 
woman’s risk of acquiring HIV and the risk of transferring HIV to her partner or to her child during 
childbirth (Brotman et al., 2010). Furthermore, studies suggest that bacteria associated with BV can 
potentially reduce the efficacy of topical anti-retroviral therapy (ARV) pre-exposure prophylaxis 
(PrEP); a crucial strategy for the prevention of HIV. In general, women are already more vulnerable to 
acquiring HIV; up to eight times more than their male counterparts (Masson et al., 2016; UNAIDS, 
2010). Johnson et al. (2012) estimated that roughly half of the new HIV infections in South African 
women in 2010 were due to other STIs. The management of these infections are thus crucial in 
preventing HIV in settings with a high burden of HIV, STIs and BV, such as South Africa (Mlisana et al., 
2012). Various studies that evaluated interventions for the prevention of HIV in South Africa also show 
that improvements in STI treatment can have a significant impact on the epidemic and can potentially 
be cost-effective (Mayaud and Mccormick, 2001; Vickerman, Terris-Prestholt, et al., 2006). 
Southern Africa has the largest burden of HIV in the world despite increases in resources earmarked 
for the epidemic which have allowed management and treatment to be improved in the region 
(UNAIDS, 2018). A large part of this burden is accounted for in South Africa, with 33% of new HIV 
infections and 29% of AIDS-related deaths in Eastern and Southern Africa in 2017 occurring in the 
country. These is the largest portions held by a single country in this region (UNAIDS, 2018). 
In South Africa the majority of STIs are managed syndromically, rather than through costlier laboratory 
diagnosis (Mlisana et al., 2012). This approach is recommended by the World Health Organization 
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(WHO) in resource-limited settings and was introduced to the South African public health sector in 
1994 (World Health Organization, 2003; Johnson et al., 2011).  Syndromic management is based on 
the identification of signs or symptoms (syndromes) of a specific STI or BV according to pre-identified 
groups. Patients are provided with treatment that will address the majority, or the most serious of 
organisms typically associated with the identified sign or symptom (World Health Organization, 2003). 
Laboratory testing, such as nucleic acid amplification tests (NAATs) and Nugent scoring (the gold 
standards for STI and BV diagnosis respectively), is expensive and requires specialised equipment and 
trained personnel. Furthermore, it does not allow for immediate results. This is problematic in low- 
and middle-income settings where the rate of return to clinics, and consequent opportunity for uptake 
of treatment, is typically very low (reported as low as 37% in some studies). In high-burdened settings 
this would also provide a window for more transmission while the patients status remains unknown.  
(Brotman et al., 2010; Masson et al., 2016). Syndromic management has thus provided a relatively 
inexpensive and seemingly more applicable alternative as it allows for patients to receive treatment 
immediately (World Health Organization, 2003). 
Various issues have, however, been raised with regards to syndromic management as a screening 
strategy for STIs since its institutionalisation in the early 2000s (World Health Organization, 2003). 
Research, however, reveals the occurrence of a large number of false positives, resulting in over-
treatment and thus excessive use of antibiotics. This phenomenon is becoming an increasingly 
alarming worldwide, as it has significant implications for the formation of drug-resistant strains of 
various bacteria. Furthermore, it results in excessive economic burden by means of wastage of scarce 
resources.  Another concern is the large portion of BV and STI cases that present asymptomatically. 
Syndromic management does not allow for the detection infection recognisable signs or symptoms of 
infection. Lastly, it relies solely on women to seek care for self-identified infections (Wajid, 2015; 
Passmore, Jaspan and Masson, 2016).  
GIFT is a POC test (a cytokine rapid test) that was developed to detect genital inflammation in order 
to identify asymptomatic infections in the female genital tract as an indication of STIs or BV. The test 
allows for the detection of inflammation caused by bacteria that also increases women’s risk of being 
infected with HIV but that is not identifiable by gold standard STI or BV laboratory tests (South African 
Medical Research Council, 2018). This test ultimately aims to identify cases that would normally be 
overlooked by syndromic management, thereby reducing the prevalence of STIs and BV as well as the 
HIV risk of women in South Africa (South African Medical Research Council, 2018). 
In order to inform on whether or not this POC test provides the South African government with a 
feasible and good value for money option for care, a cost-effectiveness study is required. The 
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estimation of the cost-effectiveness and health outcomes of the device is a primary aim of the GIFT 
project. It stipulates the development of a cost-effectiveness model from the provider’s perspective 
(South African government, Department of Health), incorporating screening and treatment costs 
incurred as well as medical costs averted through the accurate diagnosis of STIs or BV with GIFT. 
1.3. Rationale 
STIs and BV represent a massive public health issue. The WHO has set the ambitious goal of achieving 
a 90% reduction in the incidence of STIs and zero new infections by 2030. The improved detection and 
treatment of asymptomatic STI and BV cases can potentially make a significant contribution to this 
goal and forms a key part of the organization’s STI prevention and control strategies. The WHO also 
prioritizes the development of point-of-care-tests (World Health Organization, 2012b, 2016b). 
Nationally, and as part of the Western Cape’s Provincial Strategy Plan, zero new HIV and STI infections 
are a key part of the long-term vision for health of all South Africans (Western Cape Government 
Health, 2016).  Literature and practical experience suggest that there is a need to move away from 
syndromic management and towards more effective strategies for screening and diagnosis of STIs and 
BV. POC testing or screening might be more suitable in developing country settings where expensive 
laboratory testing is not feasible and where return rates to health facilities are low. GIFT provides the 
health system with such a rapid POC screening device that can potentially improve management of 
STIs and BV in low- and middle income setting such as South Africa.  
Currently, the cost-effectiveness of POC testing as a screening strategy for STIs has not been well 
established either globally or in South Africa. The cost-effectiveness of the newly developed GIFT 
device as a screening strategy is also yet to be established. The economic costs associated with 
providing universal screening for genital tract inflammation screening in the public sector has been 
estimated as part of the larger GIFT study. The original GIFT study protocol sets out for a CEA to be 
conducted and the availability of much of the cost estimates makes a CEA study of GIFT and other 
screening and diagnostic strategies more feasible in the short run. 
The findings produced by this study can potentially inform the important policy issue of resource 
allocation to STI management in South Africa. Improved management in this area of public health can 
possibly contribute to ensuring universal access to POC screening for STIs and BV for all women 






2. BRIEF LITERATURE REVIEW 
2.1. Economic and Health Burden of STIs and BV 
Kamb et al. (2008) report that STIs pose high costs on individuals in developing countries, with the 
average direct medical costs per single bacterial STI episode reaching up to three times that of the 
average daily income in low income countries. Associated indirect costs include productivity losses 
due to mortality and morbidity and other related adverse health outcomes. Globally, STIs also 
disproportionally affect the economically active population, which aggravates the economic impact of 
this public health issue. Young adults in particular, are more exposed to curable STIs, for various 
behavioural and biological reasons (Kamb et al., 2008). 
2.2. Economic Evaluation 
According to Drummond et al. (2005), economic evaluation is the “comparative analysis of alternative 
courses of action in terms of both their costs and consequences”. It encompasses the identification, 
measurement, valuation and comparison of the costs and consequences of each considered 
alternative (Drummond et al., 2005). Within the methodological field of economic evaluation, various 
approaches exist. 
One of four types are typically used; cost-minimisation analysis (CMA), cost-benefit analysis (CBA), 
cost-effectiveness analysis (CEA) and cost-utility analysis (CUA).  For all four approaches, economic 
costs of alternatives are measured in monetary terms. CMA is typically used where the alternatives 
broadly have equivalent consequences and therefore, outcomes are not measured or valued. The 
costs of the alternative courses of action are merely weighed up against each other. It is not 
considered a full economic evaluation and can be considered a subset of CEA. CBA is used when 
consequences, not necessarily common to all alternatives, are also measured in monetary terms 
(Drummond et al., 2005; Fox-Rushby et al., 2005). CUA, on the other hand, presents outcome 
measures in either quality-adjusted life years (QALYs) gained or disability-adjusted life years (DALYs) 
averted. Both these are utility measures that allows for single or multiple, dissimilar consequences to 
be compared. According to Drummond et al. (2005), CEA is suitable for scenarios where the decision-
maker is operating within a given budget and considering a range of option within a given field. In this 
type of economic evaluation, outcomes are presented in natural units, such as years of life gained, or 
number of cases detected associated with a specific strategy. According to Fox-Rushby et al. (2005), 
CEA is the most commonly used form of economic evaluation in healthcare. 
CMA and CEA provide insight on technical efficiency only, while CUA can inform on allocative efficiency 
within the entire health sector, for example. Technical efficiency refers to a situation where available 
resources are utilised so that output is maximised, and costs are minimised. Allocative efficiency on 
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the other hand, refers to where no person can be made better off without making another worse off 
(Fox-Rushby et al., 2005). CBA is unique in that it can provide insight on allocative efficiency in general 
and can thus be used to argue for increased resource allocation to the health sector itself  (Drummond 
et al., 2005). 
2.3. Cost-effectiveness Analyses of Screening and Diagnosis of STIs and BV   
A brief review of the available literature on the cost-effectiveness of different screening and diagnostic 
strategies for STIs and BV is given here. Two systematic reviews of literature on the cost-effectiveness 
of Chlamydia interventions and screening were included. Studies included in these reviews were not 
individually reviewed. 
Honey et al. (2002) conducted a systematic review of 10 studies comparing the cost-effectiveness of 
screening for Chlamydia with various laboratory tests, to testing and treating only symptomatic 
women in European populations. The authors concluded that overall, screening is a cost-effective 
alternative in terms of cases of pelvic inflammatory disease (PID) or Chlamydia prevented. NAAT 
laboratory testing was more cost-effective method of screening than the three other tests included. 
Rours et al. (2016) found similar results in a cohort of Dutch pregnant women based on cases of PID, 
preterm delivery and neonatal complications prevented. Honey et al. (2002), however, also note that 
many models lacked strong evidence to support the assumptions they made as well as sound 
effectiveness data.  
Roberts et al. (2006), another systematic review on the cost-effectiveness of screening for Chlamydia, 
critique Honey et al. (2002) on being potentially misleading with their conclusion as many of their 
studies used restricted outcome measures such as “cost per case detected” and static models and that 
the relevant limitations were not fully discussed. Roberts et al. (2006) reviewed 59 studies, mainly 
from developed countries and report that the majority of studies found the combinations of screening 
with laboratory testing and treatment to be cost-effective, but that most studies had similar 
weaknesses to those identified in Honey et al. (2002). This prevented them from making concrete 
conclusions. Two other reviews judged sound by them, however, showed that screening is cost-
effective and would even become cost-saving over a period of 4-5 years if to be implemented (Honey 
et al., 2002). 
Homan et al. (2002) assessed the cost-effectiveness of syndromic management, risk assessment and 
laboratory testing (as well as combinations of these) for various STIs among sex workers in 
Madagascar. The study found that the combination of syndromic management and regular risk 
assessment was more cost-effective than laboratory testing and risk assessment for reducing the 
prevalence of Gonorrhoea and Chlamydia (both cervical infections). The authors, however, note that 
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different results were obtained for vaginal infections and syphilis and emphasises the importance of 
disaggregate analysis across diseases (could not access full paper). Romøren (2008) investigated the 
cost-effectiveness of POC testing and syndromic management, with both the standard of care drug 
and a new one, of Chlamydia in Sub-Saharan Africa. The author finds that in the teenage study 
population, syndromic management with the new drug is the most cost-effective strategy, although 
screening with the POC test is also cost-effective. Among all age groups, only syndromic management 
with the new drug is cost-effective. This study does not, however, include additional benefits 
associated with the POC tests, such as reduced overtreatment, in their estimates (Romøren, 2008) 
This means that the POC outcomes are likely underestimated. 
Hislop et al. (2010) include cohorts from various studies across Europe, USA, China and Egypt in their 
cost-effectiveness study of six rapid POC tests compared to NAAT for the detection of Chlamydia. They 
find that NAATs is still the most accurate and cost-effective approach to diagnosing this infection, 
measured as number of true cases detected and partners notified. It is, however, noted that one of 
the POC tests would become cost-effective if the acceptance of the test by patients would increase. 
Authors also note here, the “rapid test paradox”, which refers to the lower sensitivity and specificity 
of POC tests being overshadowed by the increased treatments it ensures in comparison to laboratory 
tests which require patients returning to facilities for test results and the initiation of treatment. The 
rate of return was, however, not factored in to this evaluation. It is also noted that limited evidence 
on the effectiveness of these tests limit the comparison to NAATs (Hislop et al., 2010). 
In a Finish study, Kekki et al., (2004) found screening, with Gram-stain, and treatment of BV in 
pregnant women to be cost-effective in terms of preterm deliveries prevented, compared to the no 
screening alternative. Kuznik et al. (2012) conducted a cost-effectiveness study of rapid POC tests as 
a screening strategy for syphilis in pregnant women in Sub-Saharan Africa. These authors also found 
that screening and treatment was more cost-effective than no testing and also a cost-saving approach 
in terms of stillbirths, congenital syphilis, neonatal deaths and DALYs averted. Huntington et al., (2017) 
also conducted a study on the cost-effectiveness of three hypothetical POC NAATs  in comparison to 
standard laboratory testing, based on UK data. The POC test testing for four STIs simultaneously was 
found to be the most cost-effective in terms of reduced inappropriate treatment of STIs, STI 
transmissions and PID. All three POC test were, however, costlier, but more cost-effective than 
standard care laboratory testing. A key limitation of this study is that given the hypothetical nature of 




In order to account for differential timing of costs and outcomes, these are discounted in CEAs 
(Drummond et al., 2005). In the literature, it was found that a discounting rate of 3-5% is commonly 
used in CEA on STIs and higher rates (up to 10%) were only used when modelling secondary outcomes 
such as fertility (Honey et al., 2002). All of the studies only included direct costs as it was conducted 
from the viewpoint of the various health care providers, which were mostly national departments of 
health.  
From this brief literature review it is clear that literature on the cost-effectiveness of screening 
strategies for various STIs and BV is mixed and quite muddled in terms of study design (especially 
outcome measures) and results and conclusions. The studies are difficult to compare due the different 
STIs, screening tests and approaches and populations included in each of the models. However, there 
is clearly a gap in the literature when it comes to the cost-effectiveness of different screening 
strategies of STIs and BV in low- and middle-income countries. Furthermore, there is a need for good 
quality CEAs to inform policymaking on the issue of STI and BV management and POC screening and 
testing. 
3. AIMS AND OBJECTIVES 
3.1. Aim 
The main aim of this study is to establish the cost-effectiveness of GIFT for the screening and diagnosis 
of STIs and BV, in comparison to other relevant screening and diagnostic approaches. Economic 
evaluations, such as cost-effectiveness analyses, aim to inform decisions on resource allocation where 
limited resources are available (Mori et al., 2017).  The study will thus aim to inform on the relative 
cost-effectiveness, or value for money, of the GIFT device in the South African public health sector 
context.  
3.2. Study Objectives 
The objective of the study is to identify, quantify and value all resources associated with the identified 
screening strategies for STIs and BV in women at the primary care level to: 
1. Estimate the unit costs associated with screening and treatment of STIs and BV using each 
identified approach. This will be conducted from the perspective of the provider; the 
Department of Health. 
2. To estimate the effectiveness of each identified screening comparator. 
3. To establish the incremental cost-effectiveness ratio associated with each comparator in 
terms of women diagnosed and treated. 
4. To determine the relative cost-effectiveness of each comparator. 
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4.1. Study Design 
The study will take the form of a cost-effectiveness analysis (CEA). This involves measuring and valuing 
costs and health outcomes (effectiveness) associated with different paths of care to compare these 
strategies in terms of its value for money (Mori et al., 2017). According to the WHO the majority of 
STIs are caused by eight infections: C. trachomatis, N. gonorrhoeae, T. vaginalis infections, syphilis,  
genital herpes, human papillomavirus, human immunodeficiency virus (HIV) and hepatitis B virus 
(Kamb et al., 2008). The STIs that will be included in this analysis were identified from Masson et al. 
(2016) and Passmore, Jaspan and Masson (2016) and include C. trachomatis, N. gonorrhoeae and T. 
vaginalis; the three highly prevalent curable STIs among women in South Africa. These infections, 
along with BV, will be included in the study due to both their high prevalence in South Africa and 
association to increased risk of HIV acquisition and transmission (Passmore, Jaspan and Masson, 
2016). 
The model will be constructed and parameterised from the perspective of the South African 
government as the healthcare provider. The study will be conducted prospectively as part of the GIFT 
study, given that the device validation pilot study has not yet commenced. The GIFT study’s protocol 
sets out that the incremental cost-effectiveness ratio (ICER) of the newly developed rapid POC test be 
compared to the current standard of care; syndromic management. For this study, however, standard 
laboratory testing and GeneXpert and microscopy will also be compared in order to gather valuable 
insight on a wider range of screening and diagnosis alternatives for STIs and BV available in South 
Africa. 
4.2. Cost-effectiveness Analysis 
A decision-analytic model will be used to determine (a) the cost per woman correctly diagnosed per 
screening strategy and (b) the cost per woman treated per screening strategy. A simple decision tree 
model will be constructed using Microsoft Excel. All costs will be valued and presented in 2019 South 
African Rand (ZAR) and where necessary, costs will be adjusted for differential timing based on the 
relevant inflation rates. The model will be set-up to describe each alternative course of action, linking 
it to its relevant cost and outcome parameters. Ultimately the ICER of each strategy will be calculated 
based on the formula presented below in figure 1. In order to establish the incremental cost-
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effectiveness ratio of each comparator, the incremental costs are divided by the incremental 
effectiveness. 
Figure 1: Incremental cost-effectiveness ratio calculation 
 
(Y represents the next least costly strategy) 
Source: adapted from (Drummond et al., 2005) 
4.2.1. Screening Strategies 
The alternatives included in the analysis is based on the GIFT study protocol with the addition of 
alternatives available in the South African setting. The primary study protocol stipulates a cost-
effectiveness analysis to be conducted on the newly developed rapid POC test (GIFT) in comparison 
to syndromic management. However, to give a more accurate and holistic description of the available 
options in the South African setting, GeneXpert (for Chlamydia, Gonorrhoea and Trichomonas) and 
microscopy (for BV) and standard laboratory testing will be included in the analysis (Masson, 2018). 
The comparators that will be included in the analysis are thus: 
1. GIFT followed by Syndromic Management  
2. GIFT followed by GeneXpert and Microscopy  
3. GeneXpert and Microscopy 
4. Standard Laboratory Testing  
5. Syndromic Management  
4.2.2. Description of strategies 
4.2.2.1. GIFT followed by Syndromic Management  
Symptomatic and asymptomatic women presenting at a primary health clinic are screened for genital 
inflammation using the GIFT POC test. This involves a nurse taking a lateral vaginal swab and applying 
it to the GIFT device in the clinic. In the case of a positive GIFT test result, the woman is and treated 
according to the Syndromic Management algorithm (see 4.2.2.5) (Masson, 2018). This screening 
process was estimated to take roughly 20 minutes per patients  (Kairu, 2017) 
4.2.2.2. GIFT followed by GeneXpert and Microscopy 
Symptomatic and asymptomatic women presenting at a primary health clinic are screened for STIs 
and BV using the GIFT POC test. In the case of a positive GIFT test result, the woman is further tested 
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with GeneXpert and microscopy and treated accordingly (Masson, 2018). The GeneXpert TV and 
NG/CT assays (see 4.2.2.3.) can be run simultaneously and takes up to 90minutes to provide results 
(Gwen Stephens, Ceipheid, personal communication 2019, June 3).  
4.2.2.3. GeneXpert and Microscopy  
Women presenting at the clinic with signs or syndromes of STIs would be tested for Chlamydia (CT),  
Gonorrhoea (NG) or Trichomonas (TV) using the GeneXpert (CT/NG/TV assay) of for BV using 
microscopy. The microscopy test involves the nurse taking a vaginal swab (Peeling et al., 2006; Masson 
et al., 2014). For GeneXpert, a vaginal swab is taken from the patient and applied to the GeneXpert 
assays (Gaydos et al., 2013). Microscopy and GeneXpert are conducted at the clinic (Masson, 2018). 
4.2.2.4. Standard Laboratory Testing 
In the case of laboratory testing, a vaginal or cervical swab is typically taken by a nurse from a patient 
displaying symptoms and sent to the laboratory. Specific tests are requested testing either for a 
specific STI or a range of infections.  Patients are then informed on their results and are required, in 
the case of a positive test result, to return to the clinic for the initiation of treatment (Masson, 2018).  
4.2.2.5. Syndromic Management  
Syndromic management is based on the identification of signs or syndromes of a specific STI or BV 
according to pre-identified groups. Patients presenting at the clinic with symptoms of STIs would be 
examined by the nurse and provided with treatment that will address the majority, or the most serious 
of organisms typically associated with the identified sign or symptom (World Health Organization, 
2003).  
4.2.3. Research procedures and data collection 
The economic cost associated with each comparator will be obtained from the provider’s perspective. 
For comparators 1-3 this is will include all clinic-level costs associated with examining a patient, taking 
a specimen, analysing a specimen and providing patients with treatment. The latter will include the 
cost of drugs for treatment. Clinic-level costs refers to and includes staff time, capital, recurrent and 
overhead costs. The cost estimates for comparators 1 and 2 will be obtained from the GIFT costing 
study (Kairu, 2017) and published literature, while the cost of Standard Laboratory Testing will be 
obtained from the National Health Laboratory Services (NHLS) and all clinic level costs will be based 
on the GIFT costing study. 
For syndromic management, all clinic-level costs associated with the examination of a patient and 
providing her with treatment, inclusive of drug costs, will be obtained from GIFT study. The target 
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population will be women in the reproductive age (between the ages of 15 and 49) attending Spencer 
Road Clinic as costed in Kairu (2017). 
The effectiveness of each comparator will be modelled based on the sensitivity and specificity of each 
test or approach. These parameters will be obtained from published literature. The sensitivity and 
specificity of the biomarkers used in GIFT device will be used as a proxy for the effectiveness of the 
test itself, as the device validation study has not yet commenced. To estimate the effectiveness of 
Standard Laboratory Testing, lost-to-follow up data will also be extracted from the literature. Disease  
prevalence will be used as a proxy for the probability that a woman entering the model has an STI 
and/or BV. These estimates will also be obtained from relevant published literature.  
4.3. Sensitivity Analysis 
At conclusion of the base case model, one-waty sensitivity analyses and a threshold analysis will be 
conducted to investigate the robustness of the evaluation and the generalisability of the findings. Key 
parameters will be varied within plausible ranges. The most relevant uncertainties are expected to 
occur with regards to the GIFT test price, staff costs as well as the sensitivity and specificity of the 
screening strategies. Furthermore, lost-to-follow up rates might significantly differ between settings, 
especially urban and rural. The rates are expected to be much higher in remote, rural areas due to 
geographical location and related travel time and costs. Other parameters to be varied in the 
sensitivity analysis will be decided upon the conducting of the base-case analysis. 
5. DATA ANALYSIS AND MANAGEMENT 
Cost and effectiveness data will be estimated and presented as per section 3.2 and as described in 
section 4.2. Primary data will be captured as per the data collection tool in Appendix A and entered 
into a Microsoft Excel document. All primary collected data will be kept on a password-protected 
folder on a personal computer which will be backed up on a regular basis. The primary data will be 
accessible to the research team only. The decision analytic model will be constructed in Microsoft 
Excel and analysed accordingly. 
6. ETHICAL CONSIDERATIONS 
6.1. Ethical Approval 
This protocol will be submitted to the University of Cape Town’s Human Research and Ethics 
Committee (HREC). Ethical approval for the primary (GIFT) study has been sought and granted from 
HREC (HREC REF: 365/2017) as well as the Western Cape Department of Health. No additional 




6.2. Potential Risks and Benefits 
It is not foreseen that the study poses any potential risk or harm to any individual. There are no direct 
risks associated with collecting the relevant cost and outcome data from secondary sources. Potential 
risks in regard to the observation arm of the study will be minimised by conducting the observations 
from outside the consultation room and by the researchers having no direct contact with any of the 
patients. Furthermore, no personal identifiable information will be linked to any single observation.  
No individuals will be required to enrol in the study and the study will thus have no direct benefits nor 
pose any direct risks to anyone. The study is likely to hold indirect benefits for the society and public 
health regarding the management (including testing, diagnosis and treatment) of STIs and BV. It can 
possibly also have implications for disease prevalence and the HIV epidemic. It will inform on whether 
GIFT is good value for money and evidently, whether it is worth for the South African government to 
invest resources in this intervention. This could ultimately contribute to improved sexual and 
reproductive health among women by decreasing the prevalence of HIV, STIs and BV in communities.  
6.3. Autonomy and Informed Consent 
Since no individuals will be recruited or enrolled for the purpose of this study. Cost and effectiveness 
data, with the exclusion of the clinic observation arm of the study for comparator 4, will be obtained 
from the GIFT costing study and published literature. Primary data, collected through observation will 
not involve any interaction with patients nor will any personal information be collected, so no 
informed consent will thus be required. Access to the GIFT study and facility data is already granted 
through the GIFT study protocol. 
6.4. Confidentiality and Privacy 
Confidentiality and privacy will be assured at all times, since the study will not use or capture any 
data containing personal identifiers. Electronically stored information and data will be password-
protected and only accessible to members of the study team. Where relevant,  hard copy documents 
will be stored in a locked filing cabinet to which only the study team will have access to as well. 
7. PUBLICATION AND DISSEMINATION POLICY 
Upon completion of this study, the dissertation will be submitted for the fulfilment of the  
requirements of the Master’s in Public Health, Health Economics Degree. A policy brief aimed at the 
Western Cape Department of Health will also be constructed. Furthermore, an article will be prepared 





The study will be carried out over 9 months. 
Table 1: Study activities and timeline 
Activity 2018  2019       
Nov Dec Jan Feb Mar Apr May Jun Jul 
Finalise 
Protocol 
x x        
Full Literature 
Review  
  x x      
Obtain Ethics 
Approval  
















    x     
Clean and 
analyse data 
    x x    
Write-up      x    
Draft 
Dissertation 
     x    
Finalize 
Dissertation 
      x x  





The primary study (GIFT) is funded by the Medical Research Council.  A student bursary has 
been awarded to Elise van der Walt by the GIFT project for the conducting of this research as 
part of obtaining her MPH degree. 
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1. INTRODUCTION  
Sexually transmitted infections (STIs) have a massive impact on sexual and reproductive 
health, globally (World Health Organization, 2016b).  The burden caused by its widespread 
prevalence is not purely due to high associated morbidity and mortality but also associated 
treatment and management costs (Gaydos and Hardick, 2014). At a global level, the annual 
incidence of STIs is exceeded only by that of malaria, lower respiratory infections and 
diarrheal diseases and consequently places substantial pressure on health systems (Kamb et 
al., 2008; Torrone et al., 2018). Roughly 35 pathogens have been established as sexually 
transmissible (Chesson, Mayaud and Aral, 2017). Along with Bacterial Vaginosis (BV), one of 
the most common causes of vaginal discharge syndrome in women, this poses a vast, and 
often overlooked, challenge to public health and development worldwide; especially in low- 
and middle-income countries (LMICs) (Workowski and Bolan, 2015). 
The purpose of this study is to conduct a cost-effectiveness analysis of different screening 
strategies, including the newly developed GIFT device, for STIs and BV among women in Cape 
Town and ultimately, for the prevention of HIV. It follows a cost estimation and budget impact 
analysis of the device conducted by Kairu in 2017. The GIFT device can potentially improve 
the management of STIs and BV in low- and middle-income settings such as South Africa. 
Given the aims of this study, the objectives of this literature review were to: 
1. Develop an understanding and provide an overview of the epidemiology and 
economic burden of STIs and BV as well as the strategies for screening and diagnosis 
among women. 
2. To review the methodology of economic evaluation in healthcare and identify the 
most appropriate methods with which to conduct the required analysis. 
3. To provide an overview and appraisal of the published literature on the cost-
effectiveness of different screening and diagnostic strategies for STIs and BV to 
identify the gaps in the literature and areas for future research.  
4. To consider the affordability of GIFT in the South African context.  
The literature was sourced mainly through EBSCO HOST, PUBMED and Google Scholar. I  was 
further explored through manual search for literature cited in identified articles and 
identifying studies from relevant systematic reviews. Supplementary and grey literature, such 
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as relevant reports and guidelines were sourced through Google and from the GIFT study 
protocol.  
2.1. THE EPIDEMIOLOGY AND BURDEN OF DISEASE OF STIs AND BV 
Despite steady developments and improvements in the diagnosis, management and 
treatment of STIs, it continues to constitute a massive public health issue. Furthermore, STIs 
and BV disproportionately affect the developing world and women in their reproductive age 
(Francis et al., 2014; Van der Eem et al., 2016). In LMICS, STIs and their sequelae rank under 
the top five reasons for adults seeking healthcare (World Health Organization, 2012b).  
Most STIs are caused by one of eight pathogens: herpes simplex virus (HSV-2), hepatitis B 
virus (HBV), human papillomavirus (HPV), Chlamydia trachomatis, Neisseria gonorrhoeae, 
Trichomonas vaginalis, Treponema pallidum and the human immunodeficiency virus (HIV) 
(Kamb et al., 2008; Torrone et al., 2018). In 2012, the WHO reported that annually, around 
499 million new cases of the four most common curable, bacterial STIs (chlamydia, 
gonorrhoea, trichomoniasis and syphilis) occur globally (World Health Organization, 2012b). 
Global estimates of BV incidence and prevalence remain extremely limited (Torrone et al., 
2018). However, reported STIs and BV typically only represent 25-50% of all infections. This is 
partly because many cases, especially in women, present without any clinical s igns or 
symptoms and thus remain undiagnosed (Kamb et al., 2008; Kaida et al., 2018). According to 
Woodman (2016), BV is the vaginal disorder that most affects women in the reproductive age.  
BV is characterised by the depletion of hydrogen peroxide producing lactobacilli in the vaginal 
tract and is caused by an imbalance in the ecology of normal vaginal flora (Mcdonald, 
Brocklehurst and Gordon, 2011). It is not considered a sexually transmitted infection itself but 
is associated with various other STIs and related sequelae, such as PID and adverse pregnancy 
outcomes. Although BV is related to sexual activity, its association to other STI-related 
infections of the genital tract is ascribed to biological interactions in the vaginal flora as 
opposed to common risk factors for acquisition (Morris, Rogers and Kinghorn, 2001; 
Woodman, 2016). 
Generally, LMICs are estimated to have higher STI disease burdens than high-income 
countries (Chesson, Mayaud and Aral, 2017). Recent WHO estimates confirm that the 
majority of curable STIs occur in the developing world and that an annual incidence of 92 
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million new infections is accounted for by the African region alone (Van der Eem et al., 2016). 
The prevalence of BV is also much higher in LMICs, and Sub-Saharan Africa in particular, 
compared to the developed world. Some studies have estimated that up to 55% of women in 
these populations are infected with BV. (Cohen et al., 2012). This has significant health, 
economic and social implications. 
Most of these infections are preventable or curable with relatively inexpensive and simple 
interventions. If left untreated, however, they result in various serious sexual and 
reproductive complications in both men and women, including pelvic inflammatory disease, 
cervical and other genital tract cancers, ectopic pregnancy, adverse pregnancy outcomes such 
as stillbirths and premature delivery, urethral strictures and epididymitis. Recent studies 
indicate that STIs and BV also increase the risk of HIV acquisition and transmission (Kamb et 
al., 2008; Masson, Arnold, et al., 2015; Chesson, Mayaud and Aral, 2017).  
Poor health can pose significant costs on individuals and a society at  large ad STIs place 
significant strain on both households and national health systems, especially in LMICs  (World 
Health Organization, 2016a). Although the direct epidemiological and clinical aspects of a 
disease, such as mortality and morbidity, are necessary in determining its burden on a 
population, it is also important to understand its economic consequences (World Health 
Organization, 2009). The high prevalence of STIs in LMICs result in significant losses for 
individual and community productivity in these countries (Kamb et al., 2008). Kamb et al. 
(2008) further reports that STIs pose high costs on individuals in developing countries, with 
the average direct medical costs per single bacterial STI episode reaching up to three times 
that of the average daily income in LMICs. Productivity losses occur as an indirect effect due 
to mortality and morbidity related to STIs and its sequelae (Kamb et al., 2008).  
STIs disproportionally affects the economically active population, which aggravates the 
economic impact of this public health issue. Young adults in particular, are more exposed to 
curable STIs, for various behavioural and biological reasons (Kamb et al., 2008). The age 
distribution observed in many LMICs (relatively large youth populations) thus contributes to 
the high burden of STIs in these settings (Chesson, Mayaud and Aral, 2017). In 2012, 18% of 
the world’s youth population, aged 12-24 years, lived in Africa and this number is projected 
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to increase with 60% by 2040, to reach 466 million (Department of Economic and Social 
Affairs, 2012). 
Women and children are also more exposed to the burden of STIs (Aledort et al., 2006; 
Chesson, Mayaud and Aral, 2017). Van der Eem et al. (2016) states that globally, STIs are the 
second largest cause of quality of life lost among women (after pregnancy-related adverse 
events) and considered one of the leading causes of disability adjusted life years (DALYs) lost 
for women in their reproductive age in developing countries (Kamb et al., 2008; Naidoo et al., 
2014). Healthcare seeking for STIs among women in LMIC settings is often avoided, 
inadequate or delayed for various reasons. These include the asymptomatic nature of many 
STIs, limited sexual health awareness and access to health and the tendency to rely on home 
remedies or care seeking from traditional healers (Chesson, Mayaud and Aral, 2017; Wood et 
al., 2018).  
Various cultural values and behavioural norms, especially in the African context, can also 
further explain this phenomenon. According to Adeyemi (2011), in Africa, gender-based 
norms and power dynamics play a large role in the observed phenomenon of higher 
prevalence and incidence of STIs among women than among their male counterparts. Women 
are reported to have less power to say no to sex and especially unprotected sex, are 
frequently subjected to intimate partner violence and often stigmatised by communities 
regarding associated genital symptoms (Adeyemi, 2011; Wood et al., 2018). The misdiagnosis 
and consequent unnecessary treatment for STIs (as is common under standard of care 
practices in resource-constrained settings) can lead to violence against women, as partner 
violence can be ignited when women inform their sexual partner on their STI diagnosis and 
the need for partner treatment (Kettler, White and Hawkes, 2004; Wajid, 2015). These factors 
affect both their risk exposure to STIs as well as their healthcare seeking behaviour (Adeyemi, 
2011; Wood et al., 2018).  
STIS AND BV IN SOUTH AFRICA 
South Africa, an upper-middle income country, houses one of the largest burdens of STIs in 
the world and a significantly high prevalence of bacterial STIs (Johnson et al., 2007; Van der 
Eem et al., 2016; The World Bank, 2019). Furthermore, unprotected sex is identified as the 
largest risk factor for morbidity and mortality in South Africa; a trend observed over at least 
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the past 10 years. Although this trend is most likely largely attributable to the HIV/Acquired 
immunodeficiency syndrome(AIDS) epidemic, this also includes morbidity and mortality 
resulting from other STIs (Institute for Health Metrics and Evaluation, 2018).  
The South African public health sector serves 84% of the population (Mahlati and Dlamini, 
2015).  The vast majority of the STI burden thus falls on this sector and mainly surfaces at 
primary care level by women seeking family planning, child health or antenatal health 
services. Studies suggest, however, that the STIs treated in primary care only present a very 
small percentage of the actual burden of disease in the population, due to reasons explored 
in the previous section (Frohlich et al., 2007). C. trachomatis, N. gonorrhoeae and T. vaginalis 
infections are included in this study. These infections, along with BV,  are considered for the 
analysis due to both their high prevalence among women in South Africa and their association 
with the increased risk of HIV acquisition and transmission (Passmore, Jaspan and Masson, 
2016). Of the common curable STIs, Chlamydia is associated with the highest genital cytokine 
levels, followed by gonorrhoea, trichomoniasis and BV; indicating high associating with HIV 
(Masson et al., 2014). 
Southern Africa has the largest burden of HIV in the world, despite increases in resources 
made available for HIV over the past decade that have allowed for improved management 
and treatment of this epidemic in the region (UNAIDS, 2018b). The latest available data 
reveals that in 2017, around 36,1 million people living with HIV, globally (UNAIDS, 2018a).  
South Africa accounts for a large part of this burden with 33% of new HIV infections and 29% 
of AIDS-related deaths in Eastern and Southern Africa in 2017 incurred in the country. This is 
the largest portions held by a single country in this region (UNAIDS, 2018b). According to 
Frohlich et al. (2007), the high burden of STIs and its interaction with HIV remains a major 
concern in the whole of Sub-Saharan Africa and South Africa in particular. This phenomenon 
especially affects young women as STIs and BV are highly prevalent among women in South 
Africa who are at high risk of HIV infection (Masson et al., 2014; UNAIDS, 2018a). In general, 
women are also more vulnerable to acquiring HIV; up to eight times that of their male 
counterparts (UNAIDS, 2010; Masson, Arnold, et al., 2015). Johnson et al. (2012) estimated 
that roughly half of the new HIV infections in South African women in 2010 were due to other 
STIs. The management of STIs and BV is thus crucial in preventing HIV in settings with a high 
co-burden of HIV, STIs and BV, such as South Africa (Mlisana et al., 2012). 
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THE INTERACTION BETWEEN STIs, BV AND THE HIV EPIDEMIC 
According to Woodman (2016), the extremely high prevalence of STIs and BV in sub-Saharan 
Africa possibly represents a crucial contributing factor to the high prevalence of HIV infection 
in the region. The relationship between STIs, BV and the transmission of HIV has been studied 
widely and a positive association is strongly suggested in the literature (Johnson, Coetzee and 
Dorrington, 2005; Cohen et al., 2012; Mlisana et al., 2012; Masson, Passmore, et al., 2015).   
Inflammation in the female genital tract typically caused by STIs and BV increases the risk of 
an individual to acquire HIV by reducing the effectiveness of the mucosal barrier, recruiting 
HIV target cells and promoting HIV replication (Passmore, Jaspan and Masson, 2016; Masson 
et al., 2014). According to Brotman et al. (2010), BV infection increases a woman’s risk of 
acquiring HIV, the risk of transferring HIV to her sexual partner and the risk of transferring it 
to her child during childbirth. Studies have also recently shown that bacteria associated with 
BV might reduce the efficacy of topical antiretroviral pre-exposure prophylaxis (PrEP) used 
for the prevention of HIV (Masson and Passmore, Personal Communication, 2018, November 
18).  
BV and STIs present asymptomatic in many cases. According to Mlisana et al. (2012), the vast 
majority of BV cases are asymptomatic and Kamb et al., (2008) report that more than 50% of 
all STI cases are asymptomatic. It has been estimated as high as 75% for some STIs, chlamydia, 
gonorrhoea, trichomoniasis and syphilis, in South Africa and is especially true for the female 
population (Mlisana, 2014; Francis et al., 2018). The level of inflammation in symptomatic and 
asymptomatic women who are infected with various STIs and BV is, however, very similar 
(Masson et al., 2014). This suggests that because a vast amount of infections are left 
untreated under the current standard of care in South Africa, the management of BV and STIs 
in women, and ultimately the control of HIV remains problematic (Van der Eem et al., 2016). 
Considering the above evidence, it becomes clear that the detection and treatment of STIs 
constitutes a crucial component of HIV control, especially in the presence of substantial STI 
incidence and prevalence.  
MANAGEMENT OF STIs AND BV 
It is clear from the review the literature that the management of STIs and BV essentially exists 
of three components; prevention, detection and treatment. 
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Prevention is a crucial aspect of disease management. It involves strategies to avoid 
transmissions, and thus new infections of a disease. Various STI prevention strategies exist, 
including condom promotion, health promotion and education, social and behavioural 
change interventions and vaccination programmes (World Health Organization, 2003; 
Kularatne et al., 2018). According to Land et al. (2010), the implementation of evidence-based 
primary prevention strategies aimed at STIs is emphasized by the WHO. 
Detection can further be divided into screening strategies and diagnostic approaches. 
Globally, various STI detection guidelines have been developed which consists of several 
screening and diagnostic approaches. These approaches are often complementary to one 
another (World Health Organization, 2016). Screening is defined as testing for a specified 
infection or infections in the absence of symptoms, often in an entire population or sub-
population, while diagnostic approaches focus on the establishment of infection in the 
presence of symptoms (Land et al., 2010; World Health Organization, 2012a).  
Finally, treatment can either be diagnosis-based (following the confirmation of an infection 
through testing), presumptive (once-off or periodical administering of treatment for an STI in 
a high-risk sub-population without confirming that the infection is present) or done on a large 
scale through mass treatment (treating an entire general population for an STI) (Sahin-
Hodoglugil et al., 2003; World Health Organization, 2012a; Mlisana, 2014; Zwart et al., 2018). 
The latter is controversial despite having clear advantages such as treating asymptomatic 
patients and eliminating the need for screening tests. It raises concerns including adverse 
effects of treatment, drug resistance, resource wastage and ethical concerns regarding the 
unnecessary treatment of healthy individuals. It can also potentially instil a false sense of 
security in a population, leading to riskier behaviour. Consequently, this treatment strategy is 
neither widely accepted nor recommended in many settings (Mayaud and Mccormick, 2001). 
According to Chesson, Mayaud and Aral (2017), data from the World Bank suggests that the 
adequate treatment of curable STIs in LMICs represents one of the most cost-effective ways 
to improve global health. Failing to treat these infections, delaying treatment or providing 
inadequate treatment can result in serious health complications. 
According to the World Health Organization (2016), discretion is given to each country to 
establish the most suitable combination of prevention, detection and treatment in their 
setting, given the state of the local STI epidemic, the health system and available evidence. In 
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the following sections, the available approaches and tools for diagnosis and screening of 
curable STIs and BV will be further discussed. 
Screening approaches  
Screening refers to testing for an infection in individuals who have no clinical signs or 
symptoms and thus do not actively seek care for the disease or infection being tested for. This 
allows for early diagnosis of infections otherwise left untreated (World Health Organization, 
2016a). Considering the high levels of asymptomatic STI and BV infections, screening could 
play a crucial role in the management of these infections. Two different approaches to 
screening exist. It can be opportunistic (case-finding) or register-based (Kraut-Becher et al., 
2004; Land et al., 2010).   
Opportunistic screening involves annual or more frequent periodic screening provided during 
non-STI related healthcare visits, whereas register-based screening involves individuals being 
contacted and invited for testing based on identified risk factors (Mayaud and Mccormick, 
2001; Land et al., 2010). In some situations, opportunistic screening would be targeted at 
high-risk populations only, whereas it could otherwise be implemented for an entire 
population. High-risk populations generally include pregnant women, young adults and HIV-
positive persons (World Health Organization, 2016a). Antenatal screening for chlamydia is, 
for example, recommended by the WHO and by the Centre for Disease Control and 
Prevention (CDC) in the USA and EU, but is it rarely fully implemented (Rours et al., 2016). 
According to the World Health Organization (2016), screening remains rare in most LMICs 
because affordable point-of-care (POC) tests for this strategy remain scarce. 
Diagnostic approaches  
The diagnosis of STIs and BV involve establishing the existence of an infection in the presence 
of symptoms, using diagnostic tests. These same tests are also used in screening approaches. 
Diagnostic approaches include both aetiological diagnosis through laboratory or POC testing 
and clinical diagnosis which includes the WHO syndromic management approach (Kettler, 
White and Hawkes, 2004). This section provides an overview of the available diagnostic tools 




Clinical diagnosis involves the identification of infections by healthcare professionals only 
based on signs and syndromes presented by a patient. Identified infections are then treated 
accordingly (Kettler, White and Hawkes, 2004). Bosu (1999) defines a syndrome as a “set of 
symptoms and signs that characterize a clinical condition”. Given that resource constraints in 
many countries prohibit the routine use of expensive laboratory testing, the WHO developed 
a structured syndromic management approach in the late 1990s that exists of simple clinical 
diagnosis algorithms in the form of flowcharts. These algorithms guide healthcare providers 
to identify and manage STIs. This approach is recommended in resource-limited settings and 
is the standard of care in the South African public health sector(World Health Organization, 
2003; Johnson et al., 2011). 
Under syndromic management syndromes of a specific STI or BV is identified according to 
pre-identified groups. Patients are provided with treatment that will address the majority, or 
the most serious, of organisms typically associated with the identified syndrome (World 
Health Organization, 2003; Kettler, White and Hawkes, 2004). Appendix A provides a 
simplified version of the flowchart provided by the South African Department of Health to 
identify sexually transmitted infection when patients present with abnormal vaginal 
discharge.  The WHO approach distinguishes between seven syndromes, namely vaginal 
discharge, urethral discharge, lower abdominal pain, genital ulcer, inguinal bubo, scrotal 
swelling and neonatal conjunctivitis (Kettler, White and Hawkes, 2004; Department of Health, 
2015).  
Syndromic management is a relatively inexpensive alternative for the detection of STIs and 
allows patients to receive treatment immediately (World Health Organization, 2003). Various 
issues have, however, been raised with the approach since its institutionalisation in the early 
2000s. The accuracy of syndromic management is undermined by the various overlapping 
syndromes and signs between different STIs as well as three large amount of asymptomatic 
infections. Many studies report a large number of false positives resulting in over-treatment 
and thus excessive use of antibiotics. This is becoming a pressing problem worldwide, as it 
has significant implications for the development of drug-resistant strains of various bacteria. 
Overtreatment also causes excessive economic burden through the wastage of scarce 
resources (Kettler, White and Hawkes, 2004; Wajid, 2015). 
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Abnormal discharge from the reproductive tract can have different origins, such as the cervix 
or the vagina and can also be caused by different pathogens. These are not easily 
distinguishable, however. Due to common symptoms patients are then often treated for two 
infections, such as chlamydia and gonorrhoea, while clinically only one of the infections are 
present (Kettler, White and Hawkes, 2004; Wajid, 2015).  It is also not always possible to 
differentiate abnormal discharges, as a result of infection, from “normal” discharge. 
Consequently, these infections are not necessarily treated correctly when following the 
syndromic management algorithms, such as the vaginal discharge algorithm (World Health 
Organization, 2003). Syndromes in men, such as urethritis and genital ulcers are, however, 
more straightforward and easier identified than female genital discharge.  Women also 
remain asymptomatic much more frequently than in men. This is problematic when following 
clinical diagnosis in the female population (Mlisana, 2014; Masson, Arnold, et al., 2015). For 
these reasons, diagnosis through aetiological testing will always be considered the gold 
standard for STI detection (Kettler, White and Hawkes, 2004; Unemo et al., 2013). 
Aetiological diagnosis  
Various laboratory tests have been developed for the detection of STIs and BV (Unemo et al., 
2013). The value of any diagnostic test is largely dependent on its accuracy, the ability to 
distinguish healthy cases from unhealthy cases, and can be measured in terms of sensitivity 
and specificity. Test sensitivity is the ability to correctly identify the true positives (those with 
the disease or infections), while test specificity is the ability to correctly identify the true 
negatives (those without disease or infection (Altman and Bland, 1994; Unemo et al., 2013; 
Baratloo et al., 2015). 
Laboratory tests are commonly employed for diagnosis and screening in high-income 
countries (HICs). In LMICs, however, a lack of adequate infrastructure often excludes standard 
laboratory testing as the standard of care. Governments in these settings seldomly have the 
financial means to provide such services to the population, while the patients themselves 
frequently find these services inaccessible due to financial or geographical barriers (World 
Health Organization, 2012b).  
Laboratory testing fulfils an important role in countries who can afford these technologies, in 
terms of diagnosis as well as the establishment of antimicrobial resistance (Unemo et al., 
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2013). Generally, aetiological diagnosis for STIs can be divided into three broad categories. 
Firstly, methods exist for the detection of the microorganisms causing the infection. These 
methods include microscopy and suitable wet preparation or staining to allow the 
visualisation of pathogens (foreign microorganism causing the infection), antigen detection, 
culture and nucleic acid detection (Unemo et al., 2013). Antigen testing involves the detection 
of proteins on the surface of the pathogen. Culture testing, on the other hand , requires a 
specimen to be placed in a suitable, controlled environment for bacteria to gro w in. This 
allows the initially small number of microorganisms present in the clinical sample to multiply 
and consequently, be identified. Nucleic acid detection, which can be done using either non -
amplified or amplified methods, involves the identification of nucleic acid; a complex organic 
substance present in all living cells such as DNA (deoxyribonucleic acid) or RNA (ribonucleic 
acid). Amplification is a fairly new method that involves multiplying the nucleic acid present 
in the specimen to allow for the detection of very low initial amounts of these substances 
(Land et al., 2010; Gaydos and Hardick, 2014). Each of these methods has its advantages and 
disadvantages.  
Microscopy relies quite heavily on the expertise of the technician, involves complex staining 
procedures and often requires electricity. It does, however, provide more immediate results 
than some other approaches when it can be performed in the presence of patients and thus 
result in timelier treatment. Laboratory-based testing such as normal or amplified nucleic acid 
detection testing (NAAT), culture and antigen testing perform better in terms of sensitivity 
and specificity but require specialised personnel, advanced technical skills and specialised 
transport of specimens to ensure optimality. The waiting period between testing and results, 
often days or weeks, is also problematic in terms of lost-to-follow-up and delayed treatment 
initiation. Rapid POC tests based on these methods have overcome some of these challenges 
but dependable, high-performing tests are not yet widely available. (Land et al., 2010; Unemo 
et al., 2013) 
The second type of aetiological testing is serological testing. This approach is based on the 
detection of antibodies; the host’s response to infections. Many serological tests have been 
developed especially for the diagnosis of HIV and syphilis. One downfall of these tests is that 
antibodies can remain in the host long after successful treatment, but some have been 
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developed that can differentiate between previously treated or long-lasting infections and 
newly acquired ones (Unemo et al., 2013).  
Thirdly, aetiological tests that detect microbial metabolites in the host body, that occurs as a 
result of materials altering the pH levels in biogenic amines or genital secretions, have been 
developed. In some settings, these tests are useful when used alongside other diagnostic tools 
and is particularly important in the diagnosis of bacterial vaginosis through the whiff test and 
pH tests (Unemo et al., 2013). 
In recent years, major progress has been made in the development of POC tests for STIs. The 
development of rapid point-of-care (POC) tests for STIs has been a priority on the global 
agenda since the 1990s, while syndromic management was originally only intended as a 
temporary solution (Romøren, 2008). The WHO developed the ASSURED criteria under the 
Sexually Transmitted Diseases Diagnostics Initiative. This acronym specifies 7 criteria for any 
newly developed diagnostic test to ensure that it meets disease control requirements; 
affordable, sensitive, specific, user-friendly, robust and rapid, equipment-free (or minimal 
equipment) and deliverable (Peeling et al., 2006). 
The following sections provide an overview of the gold standard and other available 
diagnostic tools, by infection type. 
Chlamydia and Gonorrhoea  
The gold standard for the diagnosis of C. trichomatis and N. gonorrhoea is laboratory-based 
NAATs. These tests are preferred over culture, the superior option up until the 1980s, due to 
their superior sensitivity, specificity and the various available specimen collection methods 
(vaginal swab, endocervical swab or urine sample) (Unemo et al., 2013). According to Unemo 
et al. (2013) culture, however, remains an important aspect of gonorrhoea management as it 
allows the detection of antimicrobial resistance which is increasingly problematic in gonococci 
strains worldwide.   
Other types of chlamydia diagnostic tests have also been developed, such as a laboratory-
based and POC antigen tests such as enzyme-linked immunosorbent assays (ELISA) and Direct 
immunofluorescence assay (DFA). These tests, however, perform suboptimally in terms of 
sensitivity and specificity, even in comparison to culture, and are no longer recommended by 
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regulatory bodies such as the CDC in Europe and the USA for chlamydia diagnosis. (Unemo et 
al., 2013; Workowski and Bolan, 2015).  
Laboratory-based NAATs are widely used in HICs and more rapid and less expensive tests 
using the nucleic acid amplification method are also being developed. The GeneXpert CT/NG 
test is an example of a combined chlamydia and gonorrhoea polymerase chain reaction (PCR) 
NAA POC test that has been developed in the USA and is now commercially available. It is 
currently the only test of its kind that performs comparatively well to laboratory-based NAATs 
and can detect DNA of either pathogen from urine, endocervical or vaginal specimens. The 
test is ideally performed in on-site laboratories using the GeneXpert system and can present 
results in less than 2 hours. It still relatively expensive in an LMIC context and is thus not 
widely available on-site at healthcare facilities (Gaydos et al., 2013; Gaydos and Hardick, 2014; 
Mlisana, 2014). Many other rapid POC tests for these two infections do not qualify for 
widespread use due to low sensitivity, despite acceptable specificity (Aledort et al., 2006).  
Trichomoniasis  
Culture was the foundation of trichomoniasis diagnosis for several years, but laboratory-
based NAATs have also become the gold standard for detection of this infection.  Where 
NAATs with high sensitivity is not available, algorithms that include wet-mount microscopy is 
still recommended. For example, confirming a positive microscopy result with the NAAT POC 
test, like the OSOM Rapid Trichomonas Test, a rapid antigen detection test. A GeneXpert 
assay for detecting the trichomonas pathogen has also been developed. The OSOM rapid test 
is available in many developed world settings and has higher sensitivity than microscopy. It is 
less expensive than the Xpert assay and also has a shorter processing time (Unemo et al., 
2013; Workowski and Bolan, 2015; Garrett et al., 2019).  
Bacterial Vaginosis 
BV can be diagnosed using one of two methods; clinical criteria (Amsel’s diagnostic criteria 
consisting of four clinical requirements) or Gram stain using through wet-mount microscopy. 
The latter can be analysed using either Ison-Hay criteria or Nugent scoring methods. The latter 
is considered the gold standard (Unemo et al., 2013; Workowski and Bolan, 2015). 
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STI management in South Africa 
In the South African public health sector, which serves the vast majority of the population,  
STIs are managed based on the WHO clinical diagnosis approach, rather than through costlier 
laboratory diagnosis (Mlisana et al., 2012). This service is primarily nurse-driven and is mainly 
provided at the primary care level. Syndromic management has made a considerable impact 
on the management of STIs in the country. It allows for the treatment of most pathogens at 
the initial health facility visit and is relatively easy and inexpensive to implement. However, 
many infections are left untreated or inappropriately treated (Frohlich et al., 2007; Van der 
Eem et al., 2016).  
Global and local evidence suggests that there is a need to move away from syndromic 
management and towards more effective strategies for screening and diagnosis of STIs and 
BV. More specifically, there is an urgent need to improve STI management for women in 
resource-constrained settings (Masson, Arnold, et al., 2015). Laboratory testing, such as 
NAATs and Nugent scoring with microscopy, the respective gold standards for STI and BV 
diagnosis, are expensive and require specialised equipment personnel. It also does not allow 
for immediate results and more transmissions may take place during the waiting period. This 
is unattractive in low- and middle-income settings, as in South Africa, as the rate of return to 
clinics, and consequently the opportunity for treatment uptake, is very low. Some studies 
report it to be as low as 37% (Obermeyer and Osborn, 2007; Brotman et al., 2010).  Accurate 
and affordable POC tests could be extremely valuable in LMICs where expensive laboratory 
testing is not feasible and return rates to health facilities are low. It could potentially reduce 
overtreatment and ensure adequate treatment for asymptomatic cases (Peeling et al., 2006). 
According to Peeling et al. (2006), more infected patients can be correctly treated with a POC 
test of 65% sensitivity than with a NAAT with 90% sensitivity. 
Researchers at the Division of Medical Virology at the University of Cape recently developed 
an inexpensive, rapid POC test. GIFT is cytokine rapid test that was developed to detect genital 
inflammation using inflammatory cytokines as biomarkers to identify asymptomatic 
infections in the female genital tract which then indicates the presence of an STI or BV. The 
test also allows for the detection of inflammation caused by bacteria other than those 
identifiable by STI or BV laboratory tests, but which also increase women’s risk of being 
infected with HIV. This test ultimately aims to identify cases that would norma lly be 
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overlooked by syndromic management, thereby reducing the prevalence of STIs and BV and 
the risk of acquiring HIV among women in South Africa (South African Medical Research 
Council, 2018). A validation study of the biomarkers (cytokines IL-1B and IP-10) used in the 
GIFT device found a sensitivity of 77% and a specificity of 71% to establish the presence of an 
active STI. The researchers argue that, given the interaction with HIV, a test such as this that 
identifies genital inflammation, rather than aetiological testing that seeks to identify a specific 
pathogen (of which there are many) will be more useful for the prevention of HIV and 
simultaneously identifying asymptomatic infected women (Masson, Arnold, et al., 2015).  
2.2. METHODOLOGICAL REVIEW: ECONOMIC EVALUATION 
Economic evaluation is the “comparative analysis of alternative courses of action in terms of 
both their costs and consequences”. It encompasses the identification, measurement, 
valuation and comparison of the costs and consequences of each considered alternative  
(Drummond et al., 2015). This systematic comparison between two or more complementary 
and/or mutually exclusive alternatives can inform debate around efficient and equitable 
resource allocation and contribute to more transparent and rational priority-setting 
(Romøren, 2008; Hongoro, 2017). Technical and implementation issues such as the 
heterogeneity in outcome measures and methods and lack of willingness-to-pay thresholds 
within countries, however, inhibit the true impact and value of economic evaluations. This is 
especially true in developing countries where a lack of quality, routine data obstructs the 
development of high-quality and consistent studies (Romøren, 2008).  
TYPES OF ECONOMIC EVALUATION  
Within the methodological field of economic evaluation, various approaches to analysis exist. 
One of four types is typically used; cost-minimisation analysis (CMA), cost-benefit analysis 
(CBA), cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) (Drummond et al., 
2015). For all four approaches, the economic costs of alternatives are measured and 
presented in monetary terms.  
CMA is typically used where the alternatives deliver broadly equivalent consequences. 
Therefore, it is not necessary to measure or value outcomes. For this reason, it is not 
considered a full economic evaluation and viewed only as a subset of CEA (Rudmik and 
Drummond, 2012; Drummond et al., 2015). CBA involves measuring outcomes in monetary 
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terms as well. The outcomes of the alternatives are commonly monetized based on either the 
willingness-to-pay (WTP) or through the human capital (HCA) approach. The former measures 
how much individuals are willing to pay for an intervention, while the latter measures 
opportunity costs proxied by individual income  (Fox-Rushby et al., 2005; Drummond et al., 
2015).  
CUA presents outcome measures in either quality-adjusted life years (QALYs) gained or DALYs 
averted. These are utility measures that allow for single or multiple, dissimilar outcomes to 
be compared (Drummond et al., 2015). These effectiveness measures capture both the 
quantity and quality of outcomes resulting due to an intervention (Hongoro, 2017). With CEA, 
outcomes are presented in the natural units, such as years of life gained or the changes in 
blood pressure measured in millimetre of mercury (mm Hg) associated with a specific strategy 
(Drummond et al., 2015).  According to Drummond et al. (2015), this form of economic 
evaluation is suitable for scenarios where the decision maker is operating within a given 
budget and considering a range of options within a given field and mostly, with regards to a 
specific disease or group of diseases. Fox-Rushby et al. (2005) report that CEA is the most 
commonly used form of economic evaluation in healthcare. Economic evaluations published 
in medical literature, employing QALYs or DALYs as the outcome measure are often also 
labelled cost-effectiveness analyses, however (Romøren, 2008).  
CMA and CEA provide insight on technical efficiency only, while CUA can inform on allocative 
efficiency within the health sector. Technical efficiency refers to a scenario where available 
resources are utilised so that output is maximised, and costs are minimised. Allocative 
efficiency, on the other hand, refers to a situation where no person can be made better off 
without making another worse off and is more concerned with the specific combination of 
resources than resources at large (Fox-Rushby et al., 2005). Allocatively efficient levels of 
output are also technically efficient, but not the other way around.  CBA is unique in that it 
can provide insight on allocative efficiency wider than one sector (such as health) and it can 
thus be used to argue for increased resource allocation to one sector from the general budget 




Cost analysis is an essential aspect of every economic evaluation. It encompasses the 
quantification and valuation of the resources utilised by each alternative in the analysi s to 
establish the economic cost of each approach (Drummond et al., 2015). In economic 
modelling, it is important to distinguish between the identification, measurement and 
valuation of cost inputs (Raftery, 2002; Fox-Rushby et al., 2005). 
Identification 
Identification requires listing all resource inputs relevant to the programme or intervention 
to establish the scope of the analysis. Costs are included based on the perspective from which 
the analysis is conducted and the time horizon over which it is conducted. Broadly, a provider, 
patient (or household) or societal perspective can be adopted when conducting economic 
evaluations, depending on the objective of the study (Raftery, 2002; Fox-Rushby et al., 2005; 
Riewpaiboon, 2008).  
In the provider perspective, all costs incurred by a specific provider to deliver the intervention 
or programme of interest is included. This would typically consist of all direct capital, 
overhead and recurrent costs. The provider could be a public sector provider such as the  
Ministry of Health or a specific healthcare facility (e.g. provincial hospital), or it can be a 
provider situated in the private or NGO sectors.  Depending on who the payer of the relevant 
healthcare services is and often, who the analysis is commissioned by, the analysis will be 
conducted based on relevant costs incurred in the sector of focus (Drummond et al., 2015; 
Hongoro, 2017).  
The patient, or household, perspective includes all direct and indirect costs incurred by 
healthcare users when consuming these services. Direct costs include all out-of-pocket 
expenditures related to a certain episode of illness such as transport costs, drug costs and 
user or hospital fees. Indirect costs include the value of time spent seeking healthcare and 
income lost due to illness and healthcare seeking behaviour. In the household perspective 
productivity losses and time costs of all relevant members, such as the legal guardian or other 
family members, would be added (Fox-Rushby et al., 2005; Drummond et al., 2015).  
Intangible costs, such as psychological harm caused to patients due to the disease or 
intervention under study can also be included in more comprehensive analyses. The societal 
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perspective is the broadest viewpoint and includes all costs incurred by the actors providing 
and utilising a health service or intervention, irrespective of who benefits or pays. In essence, 
it is the sum of both the provider and the patient perspectives (Drummond et al., 2015).  
A distinction is made between financial and economic costs. Financial or accounting cost 
refers to the actual expenditure on resources employed in a programme or technology and is 
often also referred to as explicit costs. The economic cost of an input includes both the explicit 
and implicit costs. The latter refers to the opportunity cost of consuming or utilising one 
resource rather than another and is defined as the value of the next best alternative foregone. 
In health economics, the economic costs of all resource inputs are ideally included in cost 
analyses (Simoens, 2009; Drummond et al., 2015). 
Measurement   
Measurement involves estimating the quantity of each resource utilised in the relevant 
intervention or programme (Simoens, 2009). Resource quantities can be obtained from 
various sources such as administrative databases, direct observations, patient medical 
records, meta-analyses, clinical trials, interviews or through consensus development 
techniques such as expert opinion (Fox-Rushby et al., 2005). The method by which resource 
quantities are obtained varies by the context in which the analysis is conducted. If the 
evaluation is conducted alongside a clinical trial, data will be obtained from the case report 
forms, whereas standalone evaluations will obtain data from sources such as case notes, 
routine facility data reports or through patient or staff interviews (Drummond et al., 2015).  
The broad categories of costs to include in an economic evaluation are capital costs (e.g. 
buildings, medical equipment, land, vehicles), recurrent costs (e.g. medical supplies, labour 
costs, training materials, medicines, laboratory supplies) and overheads (e.g. utilities, 
maintenance on capital goods, administration and other central services such as laundry or 
catering) (Drummond et al., 2015). Since overhead costs are ‘shared’ between many 
departments or units within a facility or operation, it needs to be appropriately attributed to 
the relevant programme or intervention that is to be costed. There is no single, correct 
method when it comes to assigning such costs. Marginal analysis is, however, often preferred 
by economists. This involves adding or subtracting segments of an intervention to or from a 
given programme to see which costs change. This is appropriate when the choice is between 
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an incremental aspect of a programme. The choice is more often, however, between two 
programmes that will each employ the same resource(s). Another method is to establish the 
quantities of service consumed by the patient, such as the number of days in a specific ward, 
the number of laboratory tests run or the number of procedures performed, to ultimately 
determine the unit cost of the service (Angevine and Berven, 2014; Drummond et al., 2015).  
Valuation 
Valuation refers to the methods used to establish the unit price or cost of each resource input. 
In health economics, it involves placing a monetary value on resources depleted due to the 
course of the disease, its diagnosis and treatment. The total cost of the intervention or 
programme is then calculated as the product of the unit cost and the quantity of the specific 
resource used (Simoens, 2009).  
The principle of valuation of resources is grounded in the notion of opportunity costs. 
According to economic theory, in a perfectly competitive market, market prices will represent 
opportunity costs. Market prices do not always exist in the healthcare market, however, nor 
is it a perfectly competitive market. Consequently, list prices (e.g. for drug costs) are often 
used. This is not ideal since it does not necessarily reflect the true worth (cost) of the resource 
in economic terms from the perspective of the provider, for example (Simoens, 2009; 
Drummond et al., 2015). Many resources are costed based on market prices, however, 
despite the theoretical economic cost for any resource being its opportunity cost. This is a 
commonly accepted pragmatic approach, however. It is inappropriate where resource prices 
are partly subsidised by a third party such as an international donor, for example, and needs 
to be adjusted accordingly in such cases.  
Valuation of non-market inputs, such as patient or family leisure time and volunteer time, is 
also challenging. To mitigate the lack of market prices, these are often valued based on wage 
rates such as using the unskilled wage rate as a proxy for the value of volunteer time. Various 
other approaches exist, however, such as valuing leisure time at zero, average overtime 
earnings or average earnings (Drummond et al., 2015). Shadow pricing can also be employed. 
This is the notion of assigning a monetary value to a resource not ordinarily quantifiable such 
as the productivity loss of a patient who is a housewife or the value of volunteer work. This is 
typically done on the willingness-to-pay principle and by using the value of a similar resource 
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such as the minimum wage as a proxy for the value of homemaker productivity. None of these 
methods is without controversy, however (Simoens, 2009).  
Inputs can be costed based on one of two approaches; the ingredients approach (bottom-up) 
or gross-costing (top-down) (Xu et al., 2014; Drummond et al., 2015). The ingredients 
approach involves identifying, quantifying and summing every unit of a resource that is used 
in providing a health service or intervention. This is a time-consuming exercise, but yields a 
high level of precision in its estimates (Raftery, 2002; Simoens, 2009). In LMICS, this method 
is often not feasible due to the lack of available data (Hongoro, 2017). Conversely, gross-
costing involves quantifying inputs at an aggregate level by allocating an entire budget to a 
specific service according to prespecified rules. This approach is much less complex than the 
former, but often less accurate, depending on the quality of routine data collected (Raftery, 
2002; Simoens, 2009; Xu et al., 2014). In practice, a combination of these methods is often 
used, especially in settings with more limited data availability (Hongoro, 2017).  
The sources required for a costing study depend greatly on the costing approach used since 
micro-costing, for example, will require much more detailed cost data than gross-costing 
(Raftery, 2002). In the developed world, national and cross-country datasets containing cost 
data are often available. In LMICs, however, researchers must rely more heavily on individual 
costing studies in specific settings or on specific diseases. This tends to limit the 
generalisability of results (Fox-Rushby et al., 2005; Simoens, 2009).  
ESTIMATING EFFECTIVENESS 
When considering the most appropriate measure of effectiveness or health outcomes, it is 
important to consider the objective of the intervention of interest. If there are mult iple, it 
may be useful to consider a range of outcomes. The decision-maker is then presented with 
an array of options and make a judgement based on this (Simoens, 2009; Drummond et al., 
2015). This can, however, be problematic since it relies heavily on the judgement of the 
decision-maker, which is inherently value-laden, who then decides which outcome they value 
more. 
Outcomes can be measured in various ways, including mortality measures (such as deaths 
averted or life years gained), morbidity measures (such as blood pressure, disease prevalence 
or incidence), disease-specific measures (such as disease profiles or indices) or generic 
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measures (such as health profiles or indices). The latter includes the WHO quality of life (QOL) 
profile and the EQ-5D health index upon which the QALY and DALY measures are based. These 
incorporate both aspects of mortality, or the length of life, and morbidity, and are constructed 
from standardized instruments that measure quality of life and generic health status (Fox-
Rushby et al., 2005; Drummond et al., 2015). QALYs or DALYs are emerging as the preferred 
measures of health outcomes in economic evaluation (Drummond et al., 2015).  
(Drummond et al., 2015) also differentiate between intermediate outcomes, such as ‘cases of 
disease detected’ or ‘percentage reduction in blood pressure’, and final outcomes, such as 
‘life years gained’ or ‘episode-free days’. Although the latter is generally preferred  unless the 
intermediate outcome holds some unique value, the most important consideration is that the 
effectiveness measure is relevant to the objectives considered by the decision-maker. 
However, measures that relate to broader concepts such as health gain, are important for 
comparisons across spheres of the health and other sectors. Effectiveness data can be 
obtained from clinical trials, meta-analyses, expert opinion or pilot studies, given that the 
sources are judged to be relevant and of high quality (Drummond et al., 2015). 
DISCOUNTING AND ANNUITIZATION  
Economic evaluation requires a time period to be specified over which the analysis will be 
conducted. The main consideration should be to accurately portray the decision problem to 
not mislead the user of the analysis; the decision-maker (Drummond et al., 2015). It is 
generally accepted in economics that societies and individuals have a positive rate of time 
preference. Thus, all things being equal, additional consumption is preferred in the present 
or near future rather than in the future. Conversely, it is preferred to incur costs in the future 
rather than in the present or near future. Therefore, discounting is used to adjust costs and 
effects occurring in the future to the present time by expressing it as present values (Fox-
Rushby et al., 2005; Hongoro, 2017). This aims to remove temporal biases in decision-making 
such as the tendency to prefer investment in treatment, rather than prevention programs. It 
is considered appropriate to discount costs and outcomes that occur more than one year from 
the time point at which the analysis is conducted and to apply the same discount rate to both 
aspects (Angevine and Berven, 2014). 
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Some countries have guidelines that specify a discount rate, but this is not the case in many 
LMICs. The discount rate is ideally determined within the decision-making context and where 
no explicit guideline exists, it is considered acceptable to base it on the interest rate. The 
interest rate is considered to represent the opportunity cost of money spent in the present 
as opposed to in the future. Discount rates appropriate for health outcome measures are, 
however, more controversial.  In practice, it is accepted to use any discount rate as long as it 
is thoroughly explored and varied through sensitivity analysis. In the literature, 3-5% is most 
often used as the discount rate for both costs and effectiveness (Fox-Rushby et al., 2005; 
Hongoro, 2017).  
Annuitization is a method used to account for costs occurring over more than one year. 
Capital costs should be annuitized over its useful lifetime, as it represent investments made 
at one point in time but used over time. Through annuitization, a once-off cost paid for a good 
is converted into equivalent annual costs (or payments) over its useful lifetime. This is typically 
done using depreciation rates or interest rates and replacement costs (Drummond et al., 
2015).  
PRESENTATION OF RESULTS AND RECOMMENDATIONS  
The results of CEAs and CUAs are typically presented in terms of incremental cost-
effectiveness ratios (ICERs), calculated as the difference in the costs of two interventions, 
divided by the difference in the effectiveness of the interventions (see figure 1) (Drummond 
et al., 2015). 





Source: Adapted from (Drummond et al., 2015)  
These ratios can be presented on a cost-effectiveness plane, where the Y-axis represents 
changes in costs and the X-axis, changes in effectiveness (see figure 2). Each ICER obtained 
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from an economic evaluation can be visually represented as a point in one of these four 
quadrants. The point of intersection at the origin represents the baseline comparator, often 
the current standard practice, in the model. ICERs of interventions falling in the second 
quadrant are dominant and cost-saving, it both less costly and more effective than the 
baseline, while those in quadrant four are dominated and thus not cost-effective as it 
represents an option both costlier and less effective than the baseline. In theory, 
interventions with ICERs in the first and third quadrants are potentially cost-effective, but this 
will ultimately be determined relative to the other interventions presented on the plane and 
the relevant threshold value (Romøren, 2008; St John and Price, 2013; Drummond et al., 
2015). 








Source: Adapted from (St John and Price, 2013) 
The red, dashed line signifies the willingness-to-pay (WTP) or cost-effectiveness threshold 
which represents the maximum additional investment a specific society or decision-maker is 
willing to make for an additional unit of health. A strategy is deemed cost-effective if it has a 
positive ICER below this monetary threshold. The threshold is, however, not made explicit in 
many settings and where such thresholds have been specified, these are often criticised for 
being too arbitrary (Romøren, 2008; St John and Price, 2013; Drummond et al., 2015). The 
WHO has attempted to make the threshold value more unambiguous and consistent across 
settings by establishing guidelines for a cost-effectiveness threshold based on a country’s 






the relevant ICER (per DALY averted) value is less than GDP per capita and cost-effective if it 
is between 1- and 3-times GDP per capita. This threshold faces much criticism and is widely 
regarded to be irrelevant for decision making, especially in LMIC settings, as it does not 
accurately reflect the opportunity cost of health (Kahn et al., 2014; Bertram et al., 2016; 
Woods et al., 2016). The lack of evidence-based thresholds inhibits sound decision-making 
and ultimately undermines the value of economic evaluations for the health sector.  
Thresholds in South Africa  
As in most of the developing world, there is no standard WTP or cost-effectiveness 
threshold in South Africa to facilitate decision making in the health sector. However, two 
recent studies aim to provide a guide to contextualise cost-effectiveness findings in this 
setting.  
Woods et al., (2016) estimated cost-effectiveness thresholds for several countries, including 
South Africa, based on the opportunity cost of health and the statistical value of a life. It 
concludes that previously used thresholds, such as the WHO estimates,  should be avoided 
as it is likely too high. Although based on several, it is suggested that the estimates may be 
used alongside country-specific information on the opportunity costs of health care funds to 
inform decisions on resource allocation. The estimated for South Africa was USD 2,221 – 
8.909 (in 2013 PPP) and USD 1,175 – 4,714 (in 2013 prices) per DALY averted (Woods et al., 
2016).  
Meyer-Rath et al., (2017) produced estimates of a revealed WTP threshold for South Africa 
based on the South African HIV Investment Case. The threshold was derived by using the 
relationship between the budget for HIV from the three main funders and modelled 
estimates of life years saved by several HIV treatment and prevention intervention. This 
revealed a threshold, based on the budget under consideration, of USD 547–872 per life 
year saved (LYS); only a fraction of GDP per capita (2016) estimate of around USD 6000 
(Meyer-Rath et al., 2017).  Although also based on various assumptions, this revealed WTP 
threshold can be useful to guide decision making on resource allocation in South Africa.  
UNCERTAINTY  
Uncertainty around the accuracy and validity of model parameters arises as data is collected 
and assumptions are made for economic evaluation purposes (Fox-Rushby et al., 2005). In 
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any analysis it is important is to minimise uncertainty and to account for remaining 
uncertainty through statistical methods and sensitivity analyses (Rudmik and Drummond, 
2012). One of two approaches to sensitivity analysis exist for model-based economic 
evaluation, deterministic or probabilistic, but researchers often employ both.  
Deterministic sensitivity analysis involves varying either one input parameter (one-way) or 
multiple inputs simultaneously (multi-way), to explore the impact on the results (Simoens, 
2009; Drummond et al., 2015). Scenario analysis is a form of multi-way analysis that typically 
involves creating a “best-case” and “worst-case” scenario in which a range of variables is 
altered in their most optimistic and pessimistic ways, respectively. Another type is threshold 
analysis. It involves identifying the combination of variable estimates which ensures that the 
relevant cost-utility or cost-effectiveness ratio does not exceed the specified threshold  (Fox-
Rushby et al., 2005; Simoens, 2009).  
Probabilistic sensitivity analysis is carried out by running an analysis many times with a 
different set of estimate variables drawn from statistical distributions using Monte Carlo 
simulation. At completion, a cloud of points is presented on the cost-effectiveness plane that 
represents the joint statistical distribution for costs and effectiveness. Cost-effectiveness 
acceptability curves that represent the probability that each model comparator is efficient, 
applying various cost-effectiveness thresholds, can then be drawn  (Simoens, 2009; 
Drummond et al., 2015).   
2.3. EMPIRICAL REVIEW: COST-EFFECTIVENESS ANALYSES OF SCREENING AND 
DIAGNOSTIC STRATEGIES OF CURABLE STIS AND BV.  
SCOPE OF THE REVIEW 
This review is centred around the cost-effectiveness of different screening and diagnostic 
strategies for curable STIs and BV. There exists a vast body of literature on this topic, and the 
scope consequently had to be demarcated. The scope of the review was limited to CEAs and 
CUAs published in English from the year 2000 to the present,  and those related to the BV, 
chlamydia, gonorrhoea and trichomoniasis; according to those infections included in the CEA 
to follow this review. Studies on other curable STIs were included only where it was studied 
alongside one of the above-mentioned infections. Studies from HICs and studies conducted 
on men were included, although the CEA conducted this study will be conducted for women 
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in an LMIC setting. This was because of the limited amount of studies done in the latter 
populations. Cost-benefit analyses, studies conducted on age populations other than adults 
in their reproductive age and studies examining screening and diagnosis not based in 
healthcare facilities (such as home-based screening) were excluded from the review.  
Following a search of the published literature, 29 studies were identified and included, based 
on the above criteria. 
OVERVIEW OF THE LITERATURE  
Of the 29 studies, only six were conducted in LMICs, three of which in Sub-Saharan Africa. 
Two of these are South African studies (Sahin-Hodoglugil et al., 2003; Colvin et al., 2006). The 
literature is dominated by Chlamydia-related studies or studies evaluating interventions for a 
combination of chlamydia with other curable STIs. Fewer studies pertain to gonorrhoea alone, 
while only one was conducted on trichomoniasis alone. Two other studies, however,  included 
this infection in their model. Only one study analysed a BV-related intervention. See appendix 
B for a summary of the included studies.  
The review is divided into two sections; studies related to point-of-care tests and studies 
examining laboratory-based screening, clinical diagnosis culture or other diagnostic tools and 
screening strategies.  
POINT-OF-CARE TESTING  
Chlamydia 
Ginocchio et al. (2003) investigated the cost-effectiveness of different screening and 
diagnostic strategies for chlamydia, based on a hypothetical cohort of young asymptomatic 
men in the USA. The model comparators included no screening, screening with a urine-based 
ligase chain reaction (LCR) test, a DNA amplification test (for of NAAT), and pre-screening with 
a urine-based leukocyte esterase (LE) strip test that detects white blood cells (an indication 
of infection) and an LCR test following a positive LE test to confirm the results (LE-LCR).  The 
LE test is a rapid test with relatively low sensitivity (70%) and variable specificity for the 
detection of chlamydia. A dynamic decision-tree was employed in the analysis and the ICERs 
were presented as cost per additional case of PID prevented, since transmission to female 
partners and consequent complications of infection were included in the model. Ginocchio et 
al. (2003) report that the LE-LCR strategy was the most cost-effective. Although testing with 
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LCR alone prevented more PID cases than LE-LCR, it cost significantly more per male screened. 
LCR alone would become the most cost-effective strategy if the cost of the assay were to 
decline to less than US$ 18 (2000 US Dollars) or in settings with higher chlamydia prevalence 
(>5%).  
Blake, Gaydos and Quinn (2004) conducted a CEA that assessed the cost-effectiveness of 
three screening approaches for the detection of chlamydia and gonorrhoea among male 
youth entering detention facilities. The comparators were similar to that of Ginocchio et al. 
(2003) and included urine-based NAAT screening of all youths entering the facility, pre-
screening urine with a LE strip test followed by a NAAT for positive test cases and lastly, no 
screening. ICERs were reported as the incremental cost per additional PID case prevented and 
were based on a hypothetical cohort of 4000 men. Blake, Gaydos and Quinn (2004) found 
that universal screening for chlamydia and gonorrhoea with a urine-based laboratory NAAT 
in all male youths was cost-saving. Threshold sensitivity analysis revealed that it remained the 
case even at very low disease prevalence. Savings represented by this method was primarily 
due to its ability to reduce cases of PID in current and future female sexual partners.  
The difference in findings between the two above-mentioned studies are likely the result of 
the great difference in NAA test cost; Ginocchio et al. (2003) estimated it at US$ 33 (2000 US 
Dollars) according to the maximum allowable Washington State Medicaid reimbursement, 
while Blake, Gaydos and Quinn (2004) derived its estimate, US$ 10. Neither of these two 
studies, however, made cost-effectiveness conclusions based on a WTP threshold.  
Romøren (2008) employed a static decision-tree analysis to conduct a CEA on a pregnant 
population in Gabarone, Botswana. The model compared testing for chlamydia in antenatal 
clinics with a hypothetical POC test based on the effectiveness of various available POC tests 
(sensitivity ranging from 50% (baseline) to 85% and with 98.5% specificity) to syndromic 
management. Furthermore, these strategies were modelled for three approaches: 
management of all women, women under 30 only and women under 20 only, as well as for 
two different drug regimens; the existing drug and a new drug.  Romøren (2008) presented 
the ICERs as the cost per additional cases of chlamydia cured. It is concluded that the most 
cost-effective strategy for the teenage population was syndromic management with the new, 
more effective single-dose drug compared to a week-long regimen with the existing drug, but 
that POC screening is also cost-effective in this population. When testing the model at 
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increased test sensitivity of 75%, the screening strategy became as effective but less costly 
than syndromic management. Only the syndromic management strategy with the new drug 
was cost-effective across all age groups. According to Romøren (2008), the introduction of 
POC tests is, however, crucial to reduce overtreatment, improve the effectiveness of STI 
management and to potentially enhance partner notification. The authors do not employ an 
explicit WTP threshold but employ an implicit one by stating that the ICERs of all the evaluated 
comparators were below that of the current cost of spending on a curable infection spent in 
Botswana. The suitability of this comparison is, however, dubious. 
Hislop et al. (2010) compared three strategies for chlamydia screening a combined cohort 
from various studies across China, Egypt, USA and Europe. The comparators included 
screening with the Clearview POC test (80% sensitivity on vaginal swab specimens and 77% 
for urine specimens; 99% specificity for both), screening with the POC Chlamydia Rapid Test 
(CRT) (52% sensitivity for vaginal, cervical and urethral specimens combined and 64% for 
cervical specimens only; 97% specificity for all) and screening with PCR laboratory tests. The 
latter, the gold standard for diagnosis of chlamydia, was most frequently used in practice in 
these settings. ICERs were presented as the cost per additional true-positive case identified, 
treated and partners notified. Hislop et al. (2010) concluded that screening with NAATs 
remained the least costly and most cost-effective approach for the management of 
chlamydia, but that the POC CRT test might become cost-effective in a scenario where the 
acceptance of this test by patients was higher (in terms of waiting for test results and the 
location of testing) or if the test price was to be reduced. No WTP threshold is used in this 
analysis, but it was strictly not required since the strategies were all dominated by the 
baseline comparator.   
Huang et al. (2013) had a similar objective and estimated the cost-effectiveness of a promising 
new POC test for chlamydia (92.9% sensitivity; 98.5% specificity) in comparison to NAA 
laboratory testing. The CEA was conducted for a hypothetical cohort of sexually active women 
in the USA and the ICERs were presented as the cost per additional PID case averted. 
Incremental to testing for chlamydia with the NAAT, testing with the highly sensitive POC was 
found to be cost-saving in the base case scenario. Upon conclusion, Huang et al. (2013) state 
that even moderately sensitive POC tests would be efficient in settings with low return rates 
to health facilities and that POC testing is favourable since it averts considerable amounts of 
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inappropriate treatment. None of these cost-effectiveness conclusions were based on a WTP 
threshold either.   
Vickerman, Watts, et al. (2006) employed a dynamic mathematical model to establish the 
cost-effectiveness of joint screening for chlamydia and gonorrhoea in a female sex worker 
population in Cotonou, Benin. The screening comparators were syndromic management 
(standard of care) and screening with a POC test for both infections. At that time, different 
POC tests for chlamydia and gonorrhoea with high specify (>90%), but very inconstant 
sensitivity (25-85%) were available. Consequently, four different POC tests were modelled at 
different sensitivities (50, 60, 70 and 80%) but constant specificity (95%). ICERs were 
presented as the incremental cost per case of chlamydia or gonorrhoea averted and per HIV 
case averted. Vickerman, Watts, et al. (2006) reported that simultaneous screening for 
chlamydia and gonorrhoea with a POC test is a cost-effective strategy for preventing both 
infections and HIV, but that the results depend heavily on the sensitivity and costs of the test.  
However, even at a moderate sensitivity (>60%) and a test cost of US$4 (the most expensive 
test modelled in the study; 2004 US Dollars), the POC screening strategy remained cost-
effective. Furthermore, it was concluded that the number of women inappropriately treated 
would dramatically decline when using POC tests. At a sensitivity of 70% and a test cost of 
US$ 2, the ICER would be US$ 152 per additional HIV infection averted. This presented one of 
the most cost-effective HIV prevention strategies in Sub-Saharan Africa and other populations 
at the time. The judgement of the cost-effectiveness of the model comparators was based on 
the upper bound for cost-effective interventions suggested by the World Development 
Report; $70 per DALY averted or $1300 per HIV infection averted. 
Tsai et al. (2008) conducted a CEA on the management of chlamydia, gonorrhoea and syphilis 
among sexually active, symptomatic males in Taiwan. The model compared the standard of 
care (a clinical approach consisting of presumptive treatment while awaiting laboratory test 
results), syndromic management and a pure aetiological approach consisting of PCR testing 
for chlamydia and gonorrhoea. For syphilis, the latter included screening with the rapid POC 
plasma reagin (RPR) test or Venereal Disease Research Laboratory tests and confirming 
positive results with the T pallidum heamagglutination assay (TPHA). Tsai et al. (2008) did not 
present ICERs, but average cost-effectiveness ratios (ACERs) using the average cost per 
correctly treated case. It was found that syndromic management was more cost-effective for 
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treatment of chlamydia, syphilis and gonorrhoea than the presumptive treatment and 
aetiological testing approaches in terms of average cost-effectiveness ratios. These 
judgements are, however, not made based on a WTP threshold.  
Tsai et al. (2008) concluded that overtreatment resulting from the syndromic management 
approach would not present any greater problem than with the standard of care approach. 
The results of the study are, however, represented as ACERs. This metric is not commonly 
accepted in health economics for basing cost-effectiveness conclusions on as it is considered 
to be misleading.  ACERs do not consider any alternative courses of action nor does it 
maximise net health benefit associated with an alternative under consideration. 
Consequently, it does not indicate the relative value for money represented by an alternative 
and consequently, does not aid in decision-making between alternatives courses of action; 
the primary goal of economic evaluation (O’Day and Campbell, 2016).  
Turner et al. (2014) conducted a CUA based on a dynamic transmission model in a cohort of 
simulated male and female patients attending genitourinary medicine (GUM) clinics in 
England. The model compared screening for chlamydia and gonorrhoea with an NAA POC test  
(performance was not specified, but it was stated that it is comparable to gold standard NAA 
laboratory tests) to testing with gold standard laboratory NAATs. ICERs were presented in 
terms of QALYs gained and secondarily, additional transmissions, PID cases and 
overtreatments prevented. The POC test under consideration was cost-saving for chlamydia 
and gonorrhoea management. It was found that this strategy averts considerable amounts of 
inappropriate treatment and would dominate even under very pessimistic assumptions. No 
WTP threshold was employed. 
(Huntington et al., 2018) conducted a CUA on the cost-effective of four different approaches 
for testing for chlamydia, gonorrhoea, trichomonas and Mycoplasma genitalium and was also 
modelled for a hypothetical cohort of patients attending a GUM clinic in England. The model 
compared three hypothetical POC NAATs to the standard of care, which included microscopy 
for trichomonas and M. genitalium and a laboratory-based NAAT for chlamydia and 
gonorrhoea. The performance of the POC tests was based on the accuracy of available POC 
tests at the time. The screening comparators included screening with a dual POC test for 
chlamydia and gonorrhoea (98% sensitivity), a triplex POC test (96% sensitivity) for chlamydia, 
gonorrhoea and M. genitalium and finally, a quadruplex POC (95% sensitivity) test for all four 
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infections. ICERS were presented in terms of QALYs gained and secondarily, in terms of PID 
cases averted, reduced inappropriate treatment and STI transmissions prevented. 
(Huntington et al., 2018) found that incremental to the standard of care, each strategy 
became both costlier and more effective when considering the entire study population. The 
results differed between the subgroups considered (women, men-who-have-sex-with-men 
(MSM) and men-who-have-sex-with-women (MSW)) and depending on the WTP threshold 
under consideration. However, it was beyond the scope of the study to establish whether or 
not it would be feasible to implement different strategies on the subgroups. With an ICER of 
£36 585 per QALY gained (2015/2016 Pounds sterling), simultaneous screening for chlamydia, 
gonorrhoea, trichomoniasis and M. genitalium in the entire population with the quadruplex 
POC test was deemed the most cost-effective strategy. It was also the most cost-effective in 
terms of all three secondary outcomes. However, the highest WTP threshold under 
consideration was £30 000 per QALY gained (the upper threshold of the National Institute for 
Health and Care Excellence) which makes the conclusion seem counterintuitive since the cost-
effectiveness ratio was above the threshold.  
Gonorrhoea  
Aledort et al. (2005) conducted a Markov model-based CUA to estimate the cost-utility of 
different screening strategies for gonorrhoea. The study was set in USA emergency 
departments and based on a sexually active cohort of 15-year-old women who were identified 
as at high risk for developing the infection during their lifetime. The model comparators 
included routine emergency department care (no screening), screening with on-site Gram 
stain microscopy of endocervical swabs (50% sensitivity; 94% specificity), screening with 
urine-based NAATs (95% sensitivity; 99% specificity), screening with endocervical swab-based 
NAATs (90% sensitivity; 99% specificity), screening with a vaginal swab-based rapid 
immunochromatographic strip (RIS) POC test(79% sensitivity; 91% specificity) and lastly, RIS 
test on patient-collected vaginal swabs (71% sensitivity; 94% specificity). Both NAATs are 
laboratory tests. The model was stratified along three age groups: 15-19, 20-24 and 25-29 
years. ICERs were presented in terms of QALYs gained and secondarily, PID cases averted. 
Aledort et al. (2005) found that screening with the urine-based NAAT, with no screening as 
the baseline comparator, was cost-saving for women aged 15 to 29. It was concluded that this 
strategy would provide better targeted screening of asymptomatic gonorrhoea. However, 
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screening with the RIS POC test, using clinician-obtained specimens, would also become a 
cost-effective strategy if the test became less expensive than NAAT. The findings were not, 
however, based on a WTP threshold. Aledort et al. (2005) conclude that the potential of 
accurate rapid test technology holds great promise for improved management of gonorrhoea.  
The objective of Bartelsman et al. (2014) was to estimate the cost-effectiveness of the 
alternative management approaches of gonorrhoea among a group of high-risk women and 
men in Amsterdam. The study was conducted retrospectively, examining two time periods 
when alternative standards of care existed. Consequently, the model compared the screening 
of high-risk patients using a POC microscopy to only testing symptomatic patients with the 
same diagnostic tool. In the first period (2008-2009), Gram stain had 96% sensitivity in men 
and 32% in women and in the second period (2010-2011), 95% and 23%, respectively. The 
overall specificity was nearly 100% in both periods. Screening high-risk patients only was a 
cost-saving strategy and proved cost-effective for both men and women. The Gram stain 
method, however, performs significantly poorer in the detection of the gonorrhoeal infection 
in women than in men. The average cost per correctly managed consultation decreased from 
€30.25 to €27.91 (price level not stated) from the first period to the second.  Bartelsman et 
al. (2014) did not present ICERs, but ACERs (average cost per correctly managed consultation) 
and thus wrongly make cost-effectiveness conclusions based on this.  
Zwart et al. (2018) conducted a CUA on different diagnostic approaches for the detection of 
anogenital gonorrhoea in men. The study population was MSM attending an STI clinic in 
Amsterdam. The first model comparator was for symptomatic MSM to receive Gram stain 
(on-site) followed by laboratory NAA testing. Presumptive treatment was then administered 
while awaiting NAAT results if Gram stain was positive. Asymptomatic MSM were only tested 
with NAAT. This strategy was the standard of care at the time. Secondly, all MSM receive NAA 
testing. The final model comparator was for all MSM to undergo both NAAT and Gram stain 
examination. Zwart et al. (2018) calculated the ICERs (in 2016 Euros) in terms of QALYs gained 
and secondarily, cases of epididymitis averted. The research revealed that extending Gram 
staining to all MSM would not be cost-effective with the ICER (€135 371/QALY gained) 
exceeding the relevant WTP thresholds and that discarding Gram staining would result in 
health losses. Both the WHO-recommended willingness-to-pay threshold of one- and three-
times per capita GDP (€41 258 and €123,774/QALY gained in 2016) and the Dutch threshold 
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of €20 000/QALY gained were employed to reach their cost-effectiveness conclusions. The 
standard of care was the most cost-effective approach for the management of gonorrhoea in 
this population.  
Kourbatova et al. (2008) conducted a static CEA to establish the cost-effectiveness of 
occupation-based for gonorrhoea and syphilis in a hypothetical cohort of 1000 people from 
different occupational groups in Moscow, Russia. These groups included workers from the 
food industry (e.g. food handlers), market salespersons, healthcare and education providers 
and public utility workers (e.g. hotel staff). The model compared were no screening, screening 
for gonorrhoea, screening for syphilis and screening for both infections.  On-site Gram 
staining was used to test for gonorrhoea and the Wasserman reaction and microprecipitation 
reaction tests (two antigen tests used routinely in the study setting) were respectively used 
to test for and confirm syphilis infection. The ICERs (in 2003 US Dollars) were calculated as 
the cost per STI correctly treated against the common base of no-screening. They found that 
for both sexes, screening for syphilis only, and not for gonorrhoea, was the most cost-
effective strategy with an ICER of $252 per STI correctly treated. This conclusion, is, however, 
not compared to any WTP threshold which makes it difficult to truly know if this intervention 
provides a good value for money option in this setting and the intermediate outcome 
denominator makes it difficult to compare the ICER to other studies.  
Bacterial Vaginosis  
Kekki et al. (2004) is the only study fulfilling the inclusion criteria for this review that 
investigated the cost-effectiveness of interventions related to BV. Decision tree analysis was 
employed in a population of low-risk, asymptomatic pregnant women in Finland. The 
screening approaches that were compared to the no-screening strategy were, screening with 
Gram stain (sensitivity 97.1%; specificity 99.7%) and consequent treatment with either topical 
clindamycin or with metronidazole. ICERs were presented as the cost per postpartum 
complication prevented and secondarily, per preterm delivery prevented. Kekki et al. (2004) 
found that although screening for and treatment of BV in early pregnancy might not be cost-
saving, it would produce more health benefits at the same costs, making it a cost-effective 
strategy in terms of the primary effectiveness measure. When considering the alternative, 
incremental costs per preterm deliveries prevented, no-screening was the more cost-
effective approach. There appeared to be no statistical difference between the two treatment 
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regimens. In settings where the rate of pre-term deliveries was higher than in the study 
setting, the screening strategy might have become cost-saving. No cost-effectiveness 
threshold was employed in the study.  
DISCUSSION 
Despite the POC tests examined in the studies discussed above were highly variable in terms 
of performance and the infections they detect, and the studies varied greatly in terms of 
model comparators, study methods and outcome measures, there seems to be a consensus 
that there lies great potential in POC testing for STIs. Many researchers argue that it holds 
great potential for reducing overtreatment, improving the effectiveness of STI management, 
improving HIV prevention and enhancing partner notification. There is also a consensus in the 
more recent literature that the development of rapid, accurate POC tests should be made a 
priority and this is endorsed by the WHO.  
A shortfall of the results is that some of the examined POCs that were found cost-effective 
were only hypothetical test assays at the time. Two studies also wrongly used ACERs instead 
of ICERs to arrive at cost-effectiveness conclusions. Furthermore, only two of the studies 
employed explicit WTP thresholds, while one study employed an implicit threshold. This is not 
entirely due to bad practice but a lack of reliable thresholds available to researchers and 
decision-makers in these settings.  
OTHER SCREENING AND DIAGNOSTIC APPROACHES 
Chlamydia 
Postma et al. (2000) conducted a CEA based on a dynamic decision tree analysis in a cohort 
of 2403 sexually active women from a pilot study in general practitioner practices in 
Amsterdam, the Netherlands. It assessed the cost-effectiveness of five screening strategies 
for chlamydia in women.  Four of the strategies involve testing for chlamydia in women aged 
15-19 years, 15-24 years, 15-29 years or 15-34 years, using a laboratory-based LCR test on 
urine, all of which are compared to no screening. The results of the CEA were presented both 
as the incremental cost per women cured and per major outcome averted (MOA). MOA 
referred to the most significant sequelae of chlamydia infection, namely PID, infertility, 
chronic pelvic pain, ectopic pregnancy and neonatal pneumonia. The model incorporated 
reinfection rates and partner referral. Annual screening for chlamydia of all sexually active 
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women aged 15-29 was found to be cost-effective. Furthermore, at a test cost of $17 (the 
true cost at the time of analysis; 1996 US Dollars), the strategy of screening sexually active 
women aged 15-19 would be cost saving, but screening women aged 15-24 who are sexually 
active (the CDC recommendation) would become cost-saving only if the test cost were to 
decline to below $13. Despite no explicit cost-effectiveness threshold being stated, Postma 
et al. (2000) argued that all three the strategies representing screening for women below 30 
have favourable ratios. It was also argued that the inclusion of partner referral and reinfection 
was extremely important in the model as the cost per outcome would respectively increase 
by almost 100% and 60% if the parameters were to be excluded from the model.  
In another study published in 2000 (with various overlapping authors), Welte et al. (2000), 
analysed the cost-effectiveness of population-based screening for chlamydia in the 
Netherlands. The model stretched over the first 10 years of the programme. The study 
population was a simulated cohort of asymptomatic, sexually active, heterosexual individuals 
between the ages of 15 and 25. The model compared annual screening with a urine-based 
laboratory LCR test to no-screening. The cost-effectiveness results are presented as the 
incremental cost per MOA associated with each alternative. The authors found that society 
would bear net costs for population-wide chlamydia screening initially, but that it might 
become cost-saving after 3-5 years. This indicates the possible benefits from a dynamic versus 
a static modelling approach for arriving at more meaningful cost-effectiveness conclusions. 
The ICER  (in 1997 US Dollars) of screening, when considered over a 10-year period, was US$ 
492 per MOA and US$1086 when indirect costs were included, but it is unclear what these 
ratios were compared to render it cos-effective or not. Welte et al. (2000) stated that, 
depending on the budget restriction imposed, other strategies could also become cost-
effective and that it would also differ with the inclusion of only direct costs or if total costs 
were included as well. In the scenario analysis, women were excluded from the programme 
but was found unfavourable due to a small number of major outcomes averted. 
Nyari et al. (2001) conducted a CEA on different screening strategies for chlamydia in three 
regions of Hungary in a population of asymptomatic women aged 15-19 years. The authors 
employed decision-tree analysis and included no-screening, screening with a laboratory-
based ELISA (antigen) test and thirdly, screening with an amplified Gen-Probe assay nucleic 
acid hybridization (NAH) method (the predecessor of NAA method) in the model. ICERs were 
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presented as the incremental cost per cases detected and per cases prevented. Nyari et al. 
(2001) concluded that screening with Gene-Probe was the preferred strategy for chlamydial 
screening in young Hungarian women. Although screening with ELISA presented a cost-saving 
of US$ 20 per case detected and Gen-Probe an incurred cost of US$221 (price level not 
stated). The latter prevented 10 000 more cases than the former. In the base-case analysis, 
screening with ELISA was the most cost-effective alternative, followed by no-screening. When 
disease prevalence was increased, or the Gene-Probe test cost decreased, screening with the 
screening with ELISA became the more cost-effective alternative. No WTP threshold was used 
in this analysis. 
Goeree et al. (2001) employed a Markov model in their decision analysis to establish the cost-
effectiveness of seven different screening and diagnostic strategies for chlamydia. The study 
was conducted among women aged 15-24 years in the province of Ontario in Canada. The 
study comparators included: NAH or antigen diagnostic testing using endocervical swabs, 
diagnostic testing with endocervical swab-based NAAT, diagnostic testing with urine-based 
NAAT, universal screening with endocervical swab-based NAAT, universal screening with 
urine-based NAAT, screening of high-risk women with endocervical swab-based NAAT and 
lastly, screening high-risk women with a urine-based NAAT. The denominator of the ICERs 
were presented as additional chlamydia cases averted. The results of Goeree et al. (2001), 
showed that diagnostic testing and screening with endocervical swab-based NAAT dominated 
NAH and urine-based NAA testing and screening. This remained even when various 
parameters were varied in the sensitivity analysis. Furthermore, moving from antigen or NAH 
testing to swab-based NAA diagnostic testing would be cost-saving for the healthcare system 
and avert more cases of chlamydia and related sequelae. It was concluded that endocervical 
swab-based NAAT screening of high-risk women only would result in an ICER of US$ 1873 per 
additional chlamydia case averted (with endocervical swab-based NAAT diagnostics as the 
baseline comparator), while screening of all women aged 15-24 years with the same method 
would result in an ICER of US$ 5590 (price level not stated). The former is thus more cost-
effective than the latter, but no WTP threshold is used so no concrete conclusion is made with 
regards to the absolute cost-effective of these strategies. 
Gift et al. (2001) conducted a decision-analytic model to establish the cost-effectiveness of 
different testing and screening strategies for chlamydia in asymptomatic women  who also 
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have a gonorrhoeal infection, in a cohort of 1000 women attending family planning clinics in 
the USA. The model comparators included test for gonorrhoea and if positive, treat 
presumptively for chlamydia too (Co-treat); test for both infections and treat separately 
according to positive test results (Test); test for both infections and treat women who test 
positive for gonorrhoea for both infections, but treat those who only test positive for 
chlamydia, only for chlamydia (Test/Co-treat). Furthermore, they considered different tests 
in the model, namely PACE 2 Gen-Probe (NAH) and LCR (NAA) for chlamydia and culture and 
LCR for gonorrhoea. PACE 2C Gen-Probe, that allows simultaneous testing for both infections, 
was employed in the relevant strategies. ICERs were presented as the net cost per case of PID 
averted, incremental to the next-less effective comparator. Gift et al. (2001) found that 
‘Test/Co-treat’ followed by the ‘Test’ algorithm averted the most PID cases, regardless of the 
diagnostic test used. However, the former, along with ‘Co-treat’, resulted in larger 
overtreatment while the latter minimized this issue. In this study setting, as opposed to more 
high-risk settings such as STD clinics, emergency rooms or prisons, the gonorrhoea prevalence 
is typically low and often lower than the chlamydia prevalence. The coinfection rate of 
gonorrhoea and chlamydia is often, however, within or above the range of 20-40% required 
for dual therapy as suggested by the CDC. In such settings, it is recommended that 
management strategies be based upon chlamydia prevalence and not the coinfection rate. 
Therefore, in this setting, the ‘Test’ strategy (test for both infections and treat separately 
according to positive test results) was more cost-effective than treating chlamydia 
presumptively (dual therapy). These cost-effectiveness findings were, however, not based on 
a WTP threshold. 
Mehta et al. (2002) also conducted a CEA on screening strategies for chlamydia and 
gonorrhoea. The study was set in the hospital emergency department in the USA and 
conducted on a theoretical cohort of 20 000 male and female patients entering the facility 
over 6 months. The model comparators included the standard practice (clinical diagnosis by 
clinicians), screening patients aged 18-31 years with a urine LCR test, screening only patients 
aged 18-31 years who report any risk factors and following the standard practice with the 
remaining patients, standard practice combined with screening of all 18 to 31-year olds and 
lastly, mass treatment of all patients between the ages of 18 and 31 years. The cost-
effectiveness ratios were presented as the incremental cost per additional case effectively 
57 
 
treated. Findings for women and men are reported separately. Mass treatment was the most 
cost-saving alternative for both sexes, but the acceptability of this approach had not been 
established at the time. It was further noted that no exorbitant costs associated drug 
resistance that could potentially arise with such an approach, was considered. They conclude 
that the standard of care was the only other cost-saving strategy for men. This was likely due 
to the higher rates of symptomatic infections and lower management and treatment costs in  
this sub-population. For women, screening all 18 to 31-year olds in combination with clinical 
diagnosis was the second most cost-saving strategy. Mehta et al. (2002) did not compare their 
results to a WTP threshold. 
Sahin-Hodoglugil et al. (2003) conducted a CEA on the same two STIs, based on a hypothetical 
cohort of one million South African women using static decision-tree analysis. The authors 
compared syndromic management, mass treatment and gold standard laboratory testing for 
chlamydia and gonorrhoea detection and treatment among women in their reproductive age. 
The gold standard tests included culture, LCR and PCR and they modelled treatment with two 
different drugs (doxycycline and azithromycin) for all three strategies. The ICER is reported as 
the incremental cost per gonorrhoea or chlamydia case cured. The authors state that mass 
treatment with doxycycline is the most cost-effective strategy in the base case analysis, but 
this strategy remained precarious in terms of ethical considerations and antimicrobial 
resistance, as was shown in Mehta et al. (2002). Moreover, the authors did not employ any 
WTP threshold. They conclude with various advantages and disadvantages of each alternative 
but do not make clear conclusions or recommendations nor do they provide final ICERs in 
their paper.  
Kraut-Becher et al. (2004) conducted a CEA in correctional service setting in the USA.  Kraut-
Becher et al. (2004) assessed the cost-effectiveness of different programmes for the 
management of chlamydia and gonorrhoea amongst new male and female inmates in US jails. 
The model comparators included universal NAAT screening for both infections, universal 
NAAT screening for chlamydia only and thirdly, presumptive treatment for both infections. 
The ICERs are presented as the incremental cost per additional case of infection averted. It 
was found that universal screening of the female study population for both infections was 
cost-effective (ICER of US$ 3,690 per additional case of infection averted; in 2002 US Dollars), 
while screening for chlamydia only was cost-saving under baseline assumptions. For men, 
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universal screening effective (ICER of US$ 650) was not cost saving but could be considered 
cost-effective. These judgements were, however, not made based on a WTP threshold. 
Screening for chlamydia only (ICER of US$ 4,856) was more expensive than presumptive 
treatment and not sufficiently effective to make it a cost-effective strategy. In settings with a 
high prevalence of both infections, universal screening of both sexes for chlamydia and 
gonorrhoea would become cost-effective. It is concluded, however, that universal screening 
for chlamydia of both sexes could possibly be considered due to the highly costly effects of 
chlamydia and its sequelae on the female population.  
De Vries et al. (2006) conducted a dynamic CEA to establish the cost-effectiveness of once-off 
screening and subsequent treatment for chlamydia in the patient and their identified sexual 
partner(s) with a PCR test. This approach was compared to no screening in their model. The 
study population was young Dutch adults, male and female, aged 15-29 and ICERs (in 2002 
Euros) were represented as the costs per MOA averted and per PID case averted. They argued 
that although screening for chlamydia would result in a net cost that the Dutch society would 
bear, the ICER of €373 per MOA presents a cost-effective intervention against the Dutch 
threshold of €20,000 per QALY gained. The authors illustrate this with a crude calculation of 
cost-utility of their analysis and estimate this intervention to be below €1000/QALY. The 
intervention would become cost-saving when restricted to women only.  
In a second study conducted in South Africa, Colvin et al. (2006) assessed the cost-
effectiveness of the standard of care syndromic management algorithm for a wide range of 
STIs, in comparison to an enhanced package of care with components such as condom 
provision and information leaflets in addition to standard syndromic management. The 
analysis thus included the full spectrum of STIs that is managed with the syndromic approach 
in this setting. ICERs were estimated as the incremental cost per case correctly managed and 
secondarily, per case correctly treated. The CEA was conducted on simulated female and male 
patients in primary care clinics in Durban, KwaZulu-Natal. Colvin et al. (2006) found that 
patients in the clinics receiving the intervention syndromic management packages were more 
likely to receive appropriate treatment and STI management than under standard syndromic 
management. The incremental cost of this enhanced approach was $1.51 (2003 US Dollars) 
per additional patient correctly managed, which was considered a reasonable cost for the 
health improvement it provides. No WTP threshold is used in this analysis. 
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Adams, Turner and Edmunds (2007) conducted a CUA in England on a male and female 
population of ages of 16 to 44 years. The dynamic model estimates the cost-effectiveness of 
three chlamydia strategies, namely annual screening of all women, annual screening for 
women who have changed sexual partner in the preceding 6 months and annual screening 
for both men and women. These were modelled separately for different age groups (<20, <25, 
<30, <35 and <40). This was compared to the standard of care of screening for all men and 
women under the age of 25. The authors estimated both average and incremental cost -
effectiveness ratios. The ICERs are reported as the cost per MOA and per QALY gained.  The 
authors conclude that none of the investigated strategies is cost-saving for chlamydia 
management. If PID progression rates are lower than 10%, the current standard of care 
appears to be cost-effective in comparison to no-screening, while in cases of significantly low 
PID none of the screening strategies is cost-effective. In conclusion, screening of all individuals 
below the age of 20 is the most cost-effective approach in terms of the relevant threshold of 
£20 000–£30 000 per QALY (2004 Pounds sterling) gained when considering a PID progression 
rate of equal or higher than 10%, with an ICER of £ 24,103 per QALY gained. The authors, 
however, do in some instances make cost-effectiveness conclusions based on ACERs.  
In another study, Ong et al. (2016) conducted a CUA to estimate the cost-effectiveness of 
different chlamydia screening approaches for young pregnant women, aged 16-25, in 
Australia. The model comparators were no screening, selectively screening only women aged 
16-19 and/or those reporting more than one sexual partner in the preceding year and 
screening all women in the study population. The ICERs were presented in terms of QALYs 
gained. They reported that screening all women aged 16-25 for chlamydia during an antenatal 
visit is cost-effective in comparison to the other two strategies under consideration. The ICER 
of AUD 34,931 (2014 Australian Dollars) is well below the common threshold of AUD 50,000 
in the Australian context. This strategy only loses its cost-effective status in cases where 
disease prevalence is very low (<3%), test or clinician costs almost double.  
Rours et al. (2016) employed a static decision tree analysis to estimate the cost-utility of 
screening for chlamydia compared to no screening. The study population was pregnant Dutch 
women and the diagnostic test employed was a urine-based laboratory NAAT. The authors 
reported the ICERs as the incremental cost per QALYs gained. The results from Rours et al. 
(2016) show that universal screening for chlamydia would be cost saving if the test price does 
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not exceed €22 (2009 Euros). This strategy, compared to the Dutch threshold of €20,000 per 
QALY, is cost-effective in this setting even when varying various parameters in the sensitivity 
analysis. According to the study, screening could become even more cost saving if pregnant 
women or women below the age of 30 years were targeted.  
Gonorrhoea  
Bernstein et al. (2006) conducted a static CEA on a theoretical cohort of 10,000 women 
seeking care in the private sector in the USA. The objective of the study was to estimate the 
cost-effectiveness of different screening algorithms, using urine-based NAATs, for the 
detection of gonorrhoea in this population. These algorithms included; screening women 
younger than 25, screening women younger than 30, screening women younger than 25 
reporting any risk, screening women younger than 30 reporting any risk and lastly, screening 
women younger 30 or those reporting risk of any age. Risk factors included pregnancy, 
acquisition of a new sexual partner in the preceding month and drug use. The ICERs from this 
study were reported as the cost per additional case treated and each algorithm was compared 
incrementally to a no-screening alternative. The authors reported that the most cost-effective 
approach would be to screen all women below the age of 25 who report any risk factor, for 
gonorrhoea and that this could reduce untreated infections with up to 30%. This strategy 
would also become cost-saving when disease prevalence rises to above 4.75% (compared to 
3% at baseline). However, this might be a more realistic scenario in cases of specific 
populations such as emergency department patients or at correctional  facilities, and the 
authors conclude that in general, population-based screening is likely to pose a net cost. 
Furthermore, the introduction of POC testing in this model might further enhance the cost -
effectiveness of these screening algorithms. No WTP threshold is used in this analysis.  
Trichomoniasis 
Lazenby et al. (2014) conducted a CEA to estimate the cost-effectiveness of screening, 
treatment and follow-up of trichomoniasis in HIV-positive women in the USA. This was the 
only study conducted on this infection alone that met the inclusion criteria for this review. 
The model comparators were no screening and screening using culture. 200 women were 
included in the study, 100 who were screened and 100 who were not. The ICERs are calculated 
as the incremental cost per HIV transmissions averted.  Lazenby et al. (2014) found that the 
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screening of HIV-positive women dominated the no-screening approach. The former 
represented the CDC guidelines at the time. Screening for Trichomonas vaginalis in this 
population could prevent up to 350 new HIV infections per year, a substantial number of cases 
in the USA setting, as well as provide cost savings. The perspective from which the study was 
conducted in the analysis was not clearly stated but based on the costs included (direct 
medical costs associated with screening and treatment of STIs and HIV treatment) it appears 
to be that of the healthcare provider. These judgements were not made based on a WTP 
threshold. 
DISCUSSION 
Most studies comparing screening to no screening or diagnostic testing only found the former 
to be the more cost-effective alternative and even cost-saving in some instances. However, 
these results vary greatly in terms of age groups and sub-population. Two studies found mass 
treatment to be the most cost-effective approaches for managing chlamydia and gonorrhoea 
and a range of STIs, respectively. The acceptability of this method, from both an ethical and a 
health perspective, is highly questionable and has become increasingly so in recent years 
(Mayaud and Mccormick, 2001; Mehta et al., 2002; Sahin-Hodoglugil et al., 2003). A major 
limitation in this body of work, like in the previous section, is the absence of a cost-
effectiveness (or WTP) thresholds when making cost-effectiveness conclusions.  
SUMMARY  
The literature on the cost-effectiveness of different screening and diagnostic strategies that 
have been reviewed varies greatly in terms of study design, setting and methods. Given that 
four different infections are included in the review makes it even more challenging to 
compare the findings.  
However, some common trends are found in the literature. Firstly, there is a rationale for the 
development of rapid, accurate POC tests in and further investigating the cost-effectiveness 
thereof in LMIC settings. Many studies emphasise the need for the development of rapid and 
accurate POC tests and increasing pressure is placed on this issue in the policy environment. 
The disproportionate amount of HIC research studies in the literature further points to the 
need to investigate these issues in LMICs where the burden of disease is the largest.  Secondly, 
given the high level of asymptomatic infections, screening with accurate and rapid POC tests 
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has great potential to be cost-effective in comparison to diagnostic testing approaches. Many 
studies showed that where adequate disease prevalence is present and return rates to health 
facilities are low, approaches that allow immediate diagnosis and treatment h ave the 
potential to be highly effective strategies at sufficiently low cost. Thirdly, strategies such as 
mass treatment and clinical diagnosis (syndromic management) need to be considered all the 
more carefully for various ethical and health reasons such as the rise in antimicrobial 
resistance globally. Mass treatment does, however, occur less in more recent work as an STI 
management approach.  
Overall, there is a gap in the literature in LMICs and Africa, where the brunt of the diseases 
occurs. Furthermore, the literature is largely focused on chlamydia as well as chlamydia-
gonorrhoea coinfection. While these two diseases are highly prevalent and remain  a major 
concern, other curable STIs and BV cannot be neglected especially when considering the link 
to HIV acquisition and transmission. There remains a need to find cost-effective interventions 
to decrease the prevalence and incidence of these infections and large potential for it to play 
an important role in HIV prevention. 
The advancement of a rapid test such as the GIFT device holds great promise for the 
management of STIs and BV amongst women in South Africa and potentially, o ther LMIC 
settings. The cost-effectiveness of this device has, however, not been established. This will be 
the primary objective of this research study.  
2.4 AFFORDABILITY OF GIFT IN THE SOUTH AFRICAN CONTEXT 
A previous sub-study of the GIFT project aimed to estimate the cost and budget impact of 
implementing GIFT in primary healthcare facilities in South Africa. Costs of genital 
inflammation screening were estimated from the provider’s perspective for women aged 
15-49 years using a micro-costing approach. Costs were estimated for two clinics, the 
Desmond Tutu HIV Foundation youth clinic (DTHF) and the University of Cape Town Student 
Wellness Service (UCT SWS), over one year. The unit estimates obtained were utilised in the 
budget impact analysis for countrywide implementation.  
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The cost per woman screened for genital inflammation was estimated to be $24.26 at DTHF 
and $14.32 at UCT SWS, based on 2016 cost and utilisation data. These estimates proved 
sensitive to clinic utilization rates, personnel costs and population coverage rates. 
Scaling up, a total cost ranging between $107,183,655 (for a semi-private facility) and 
$183,062,066 (for an NGO-funded facility) was estimated at country level. This respectively 
represented 10% and 17% of the available budget for HIV/AIDS at the time; a share 
considered to significantly high when considering the array of other existing interventions 
and new ones competing for funding (Kairu, 2017). This was observed amidst a declining 
trend of national budget allocation to the health sector; going from  14.5% in 2011 to 14.2% 
in 2014. Kairu (2017), however, concludes that this intervention has the potential to have a 
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COST-EFFECTIVENESS ANALYSIS OF DIFFERENT SCREENING AND DIAGNOSTIC 
STRATEGIES FOR SEXUALLY TRANSMITTED INFECTIONS AND BACTERIAL 
VAGINOSIS IN WOMEN AGED 15-49 YEARS ATTENDING PRIMARY HEALTH 
CARE FACILITIES IN CAPE TOWN 
 
ABSTRACT  
Objective    Genital inflammation associated with sexually transmitted infections (STIs) and 
Bacterial Vaginosis (BV) is considered a key driver in the HIV/AIDS epidemic. A new rapid 
point-of-care (POC) test that detects genital inflammation in women was recently developed 
by researchers at the University of Cape Town. The objective of this study was to establish 
the cost-effectiveness of this novel intervention relative to other relevant screening and 
diagnostic strategies for the management of STIs and BV in women.  
Methods      A decision analysis model was developed to estimate the cost and health 
outcomes associated with five different screening and diagnostic strategies for women 
seeking care in the South African public health sector. A decision tree was constructed, and 
all cost and effectiveness parameters were obtained from published and unpublished 
literature. The model incorporated all clinic-level and treatment costs associated with 
diagnosing and treating a single episode of disease. The main outcome measure was the 
effectiveness of each approach in correctly diagnosing an STI or BV in women, proxied by the 
sensitivity measure of diagnostic test or approach. One-way sensitivity analysis and threshold 
analysis was conducted to test key uncertainties and assumptions in the model. 
Results     In the base-case scenario, screening with GIFT and following with syndromic 
management for GIFT-positive cases, was the most cost-effective strategy with an ICER of 
$2.60 per women diagnosed with an STI(s) and/or BV. This strategy remained the most cost-
effective even when a variety of parameters were varied in one-way sensitivity analyses. A 
threshold analysis on GIFT’s sensitivity revealed that the strategy would remain the most cost-
effective unless the sensitivity of the test assay decreased below 14.83%.  
Conclusion From the perspective of the South African government, screening with GIFT and 
treating positive cases according to syndromic management guidelines is the most cost-
effective strategy for the management of STIs and BV in women in the reproductive age, but 
implementation at national level would not be affordable. The newly developed rapid POC 
has the potential to significantly improve the management of STIs and BV in women through 
identifying asymptomatic women and at the same time reducing their risk of HIV infection. 
However, this analysis presents only a first step in establishing the cost-effectiveness of these 
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INTRODUCTION 
Sexually transmitted infections (STIs) represent a significant challenge to global public health. 
In 2012 the World Health Organization (WHO) reported that annually, around 499 million new 
cases of the four most common curable STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, 
Trichomonas vaginalis and Syphilis infections) occurred globally (World Health Organization, 
2012). Recent WHO estimates confirm that the majority of these occur in the developing 
world and that an annual incidence of 92 million new infections is accounted for in the African 
region alone (1). Some studies have also estimated that up to 55% of women in Sub-Saharan 
Africa are infected with BV (2). STIs and BV are considered one of the leading causes of 
disability adjusted life years lost in women (3). If left untreated, STIs and BV can lead to various 
serious sexual and reproductive complications, and research indicates it increases the risk of 
HIV acquisition and transmission (3–6).  
South Africa houses one of the largest burdens of curable STIs in the world, with high 
prevalence in women who are at high risk of HIV (7–9). Given that the public health sector 
serves around 84% of the population, the vast majority of this burden rests on the National 
Department of Health (10).  In the public health system, most STIs are managed 
syndromically, rather than with resource-intensive etiological diagnosis (11). Under this 
approach developed by the WHO, syndromes of a specific STI or BV are identified according 
to pre-identified groups of signs and symptoms. Patients are then provided with treatment 
that will address the majority, or the most serious, of organisms typically associated with the 
identified syndrome (see Appendix A.1) (11,12).  
Given that many cases, especially in the female population, are asymptomatic (estimated as 
high as 75% in some studies (13,14)) many cases are missed under the current standard of 
care since these women do not seek care (15,16). The accuracy of syndromic management is 
further undermined by the various overlapping syndromes and signs between different STIs 
(17). Research done in South Africa suggests limited knowledge of nurses in the public sector 
regarding appropriate treatment for the various STI syndromes (18,19). Some studies also 
report low specificity of this approach, resulting in overdiagnosis and -treatment and thus 
excessive use of antibiotics. The latter has implications for the development of drug-resistant 
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strains of various bacteria which is a growing concern, globally (12,17). Globally and locally, 
there is a need to move away from syndromic management and towards more effective 
strategies management of STIs and BV. More specifically, there is an urgent need to improve 
STI management for women in resource-constrained settings (5). Research also suggests that 
improvements in STI management can have a significant impact on HIV prevention, especially 
in settings where both HIV and curable STIs are highly prevalent (16,20,21) 
The gold standard for diagnosing STIs are laboratory-based nucleic acid amplification tests 
(NAATs) and microscopic identification through Nugent scoring for BV (5,22,23). These 
methods are expensive and resource-intensive, making it unfeasible in resource-constrained 
settings (5). Furthermore, it does not allow for immediate results and requires that patients 
return to health care facilities to obtain results and receive treatment. More transmissions 
may take place during the waiting period and the rate of return to clinics, and consequently 
the opportunity for treatment uptake, is often very low in these settings. Some studies report 
it to be as low as 11% in the African context (24,25).   
With the WHO’s ambitious goal of a 90% reduction in the incidence of STIs and zero new 
infections by 2030, the improved detection and treatment of asymptomatic STI and BV cases 
form a key part of the organization’s STI prevention and control strategies. In this context, the 
WHO has prioritized the development of relevant point-of-care (POC) tests (26,27). 
Nationally, under the new National Sexually Transmitted Infections Strategy, and as part of 
the Western Cape’s Provincial Strategy Plan, zero new HIV and STI infections also form part 
of the long-term vision for public health in South Africa. This is within the context of the 
overarching framework for health which strives to universal coverage for all and vulnerable 
populations in specific.  (28,29).  
In reaction to growing concerns about the affordability of etiological diagnosis and the 
widespread concern with syndromic management, more rapid and less expensive NAATs have 
been developed. Cepheid’s GeneXpert CT/NG test is an example of a combined chlamydia 
and gonorrhoea POC NAAT from the USA that is commercially available in South Africa. A 
similar assay has also been developed detecting trichomoniasis; GeneXpert TV. These tests 
perform comparatively well to laboratory-based NAATs and are ideally performed in on-site 
laboratories using the GeneXpert system. It can present results in roughly 90 minutes, but is 
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still relatively expensive in an LMIC context, however, and is thus not widely available on-site 
at health care facilities (6,30,31).  
Recently, researchers at the Division of Medical Virology at the University of Cape 
developed GIFT (Genital Inflammation Test): a relatively inexpensive, cytokine POC rapid 
test that detects inflammatory bacteria in the female genital tract. STIs and BV cause genital 
inflammation, regardless of other symptoms such as vaginal discharge or genital ulcers 
being present. The measurement of key inflammatory cytokine biomarkers with a rapid POC 
test can thus potentially identify asymptomatic cases that are otherwise missed and 
consequently, women who are at an increased risk of acquiring and transmitting HIV. 
Identified women would then be treated immediately according to syndromic management 
guidelines (Masson and Passmore, Personal Communication, 2018, November 18). The 
device has already between validated in a biomarker validation study and is to be rolled out 
in a cross-sectional validation study in Cape Town clinics to evaluate and optimize its 
performance (Masson and Passmore, Personal Communication, 2018, November 18; 29).  
Currently, limited research is available on the cost-effectiveness of screening with POC tests 
and STI management in general in LMICs and Africa. Furthermore, the cost-effectiveness of 
this novel test device has not yet been established. However, a cost estimation for this 
intervention at clinics in Cape Town for women aged 15-49 years, as well as a budget impact 
analysis of implementing it in all primary health facilities across South Africa , has been 
conducted by Kairu³³. The cost per woman screened for genital inflammation was estimated 
to be $14.32 at a semi-private facility and $24.26 at an NGO-funded facility. Scaling up, a total 
cost ranging from $107,183,655 and $183,062,066 was estimated. This amounted to roughly 
10%-17% of the total available budget for HIV and AIDS; suggesting that this would be highly 
costly in the South African setting.  
A decision analysis model was developed using cost and probability estimates from existing 
literature to estimate the cost-effectiveness of five screening and diagnostic strategies for the 
three highly prevalent curable STIs in South Africa, Chlamydia trachomatis, Neisseria 
gonorrhoeae and Trichomonas vaginalis infections, and BV. These infections were considered 
for the analysis due to both their high prevalence in South Africa, but mainly their clear 






Decision Analysis Model  
A decision tree (see Appendix A.2) was constructed in Microsoft Excel to estimate the cost-
effectiveness of five different screening and diagnostic strategies for STIs and BV in women in 
the reproductive age (15-45 years) (35) entering the South African public health sector at 
primary care level. Economic costs and clinical effectiveness were estimated with the 
following screening and diagnostic strategies for C. trachomatis, N. gonorrhoeae, T. vaginalis 
and BV:  
1. Syndromic management of symptomatic women seeking healthcare  
2. Screening all women entering primary care facilities with GIFT followed by syndromic 
management for GIFT-positive cases (GIFT-SM) 
3. Screening with GIFT followed by testing with GeneXpert NG/CT and GeneXpert TV 
assays and microscopy for GIFT-positive cases (GIFT-Xpert-Microscopy) 
4. Screening with GeneXpert (NG/CT and TV) and microscopy alone (Xpert-Microscopy) 
in health facilities. 
5. Screening with gold standard laboratory testing (PCR-Microscopy) at an off-site 
laboratory.  
The model was populated with the probabilities of events based on estimates from published 
literature. These strategies were included based on the primary GIFT study protocol and 
expert opinion on the current circumstances and available technologies in the public health 
sector (Nigel Garret, email correspondence, 2018, August 29; Masson and Passmore, Personal 
Communication, 2018, November 18). Model outcomes were compared using incremental 
cost-effectiveness ratios (ICERs). In the model, the latter was measured as the additional cost 







Figure 1: Extract from the full decision tree: GIFT, followed by GeneXpert and Microscopy for 






TP= true positive; FN = false negative; TN = true negative; FP = false positive  
Data 
Effectiveness  
The effectiveness of each approach was estimated based on the sensitivity and 
specificity of each approach, with the primary outcome being appropriate diagnosis 
and treatment administered. The latter was proxied by the sensitivity measure of each 
diagnostic test or approach. These parameters were obtained from published 
literature and are shown in table 1.   
Where two or more tests are performed simultaneously in a branch of the decision tree, such 
as GeneXpert and microscopy, average effective measures were used.  
Model probabilities  
The probability of events in the model was obtained from published literature. The proportion 
of patients lost to follow-up (LTFU) in the laboratory testing arm was based on published 
literature related to HIV testing in Africa as no literature on LTFU rates for STI testing exists in 
these settings (25). The prevalence of BV and the three STIs was based on estimates from 
South African studies conducted on women in the reproductive age. The overall, average 




Table 1: Sensitivity and specificity of diagnostic tests and approaches and model strategies in 
detecting sexually transmitted infections and BV in women in their reproductive age in South 
Africa  





Syndromic Management      
Any discharge causing 
STI 
10.5% 96.0% 89.5% 4.0% (16) 
CT 13.9% 92.8% 86.1% 7.2% (16) 
NG 17.9% 92.8% 82.1% 7.2% (16) 
TV 13.8% 93.5% 86.2% 6.5% (16) 
BV 10.0% 94.4% 90.0% 5.6% (16) 
GIFT For detecting genital 
inflammation 
77.0% 71.0% 23.0% 29.0% (5) 
GeneXpert for detecting CT 100.0% 97.6% - 2.4% (36) 
GeneXpert for detecting NG 100.0% 100.0% - - (36) 
GeneXpert for detecting TV 96.4% 99.6% 3.6% 0.4% (37) 
GeneXpert (average) 99.4% 99.5% 0.6% 0.5%  
Laboratory PCR (CT,NG & TV) 100.0% 100.0% - - (23) 
Microscopy (BV) † 100.0% 100.0% - - (23) 
*Includes asymptomatic cases 
** Including BV 
†Laboratory- and clinic-based, no difference between the two (Nigel Garret, personal communication, 2019, 
May 29) 
 
Table 2: Base, low and high estimates of the probability of events in the model 
Variable Low  Base case High Reference 
Disease Prevalence*     
Chlamydia  4,2% 15.4% 32,8% (1,7,13,14,16,38–
44)  
 
Gonorrhoea 1,8% 5.9% 10,9% 
Trichomoniasis  3,0% 10.8% 20,3% 
Bacterial Vaginosis 33,7% 44.5% 53,0% 
Clinic return rates 11.0% 20.0% 49% (25) 
*Based on the average prevalence from 11 studies done in South Africa from 2011-2018 
**Of all three STIs and BV 
 
Costs 
The cost of each subtree of the decision tree was based on estimates obtained from 
unpublished literature some external institutions such as the National Health Laboratory 
Service (NHLS) and Cepheid. The model incorporated all clinic-level capital and recurrent costs 
associated with each strategy for diagnosing and treating a single episode of disease. All 
screening strategies included the cost of a standard clinic visit, a physical and speculum 
examination (35) and treatment costs. In accordance with Kairu³³, no additional programme 
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start-up costs were included for GIFT strategies, expect training of personnel to administer 
the test. Where applicable, it also included the cost of taking a specimen, operating a test 
assay and obtaining results. Costing was done from the provider’s perspective (Department 
of Health) and was inflated to 2019 Rand and converted to US$ based on the average 
exchange rate for 2019. All relevant cost data is presented in table 2.  
Table 3: Cost of screening or diagnosis and treatment per patient  
Variable Cost (2019 ZAR) Cost (US$)* Reference  
COMPONENT COSTS 
Clinic visit** 192.45 13.44 (33) 
Medical consumables for 




Specimen transport¶ 18.87 1.32 (45) 
GIFT test (assay, consumables, 
equipment, training staff to 
use GIFT) 
21.41 1.50 (33) 
Testing with quadruplex PCR 
(NG,CT,TV) (outsourced 
service, quoted price) 
473.39 33.07 
 
NHLS state price list, 
2018 
Testing with laboratory-based 
microscopy (outsourced 
service, quoted price) 
42.67 2.98 NHLS state price list, 
2018 
UNIT COSTS 
Syndromic Management 192.45 13.44 (33) 
Screening with GIFT 213.09 14.89 (33) 
Screening with GeneXpert 














   CT treatment 8.71 0.61 (48) 
   NG treatment 13.58 0.95 (48) 
   TV treatment 1.57 0.11 (48) 
   BV treatment 1.57 0.11 (48) 
   Syndrome A treatment†  13.08 0.91 (48,49) 
   Syndrome B treatment‡ 14.59 1.02 (48,49) 
* R1 = US$ 14.32 (Average exchange rate 2019)  
**Includes standard visit to family planning clinic and physical (vaginal) examination. 
¶ For single specimen transported from clinic to NHLS. 
†According to SM Vaginal Discharge algorithm: treat for BV and/or vaginal candidiasis. 




The cost of a standard clinic visit and examination, as well as screening with GIFT, was based 
on estimates from Kairu³³. This was included in the cost estimate,  at least partly, of all the 
strategies, depending on the component costs included in the cost estimates obtained from 
the literature. 
The cost associated with screening with GeneXpert NG/CT and TV assays was mainly based 
on an unpublished study by Stime et al.⁴² Capital and overhead costs of a standard clinic visit 
was added to this estimate since this was not included by Stime et al. ⁴² The cost of laboratory 
testing was mainly obtained from the quoted NHLS price since service is outsourced from the 
Department of Health. The total unit cost, however, included a standard clinic visit, taking of 
specimens as well as the transport cost of two specimens.  
Drug costs were obtained from the latest available Western Cape Department of Health’s 
master procurement catalogue at the time of analysis (April 2019) and treatment regimens 
are based on the guidelines for STI treatment in South Africa. Given that syndromic 
management is mainly followed in the public health sector, guidelines do not specify 
treatment regimens for individual infections, but rather for groups of infections with similar 
symptoms (see guidelines in Appendix A.1). Costing of treatment for individual infections 
were based on regimens used in Garret et al.³⁵ Average treatment cost was assumed in the 
base case scenario for simplification.  
Model Assumptions  
Only women in their reproductive age, ages 15-49 years, were included following Kairu³³. This 
age group typically carry the highest burden of social and psychological consequences of STIs 
and are typically most susceptible to STIs and BV (WHO 2013). For syndromic management, 
it was assumed that all women who have symptoms seek care and accepted consequent 
treatment. All screening strategies were based on opportunistic screening of any woman 
entering a primary healthcare facility. It was assumed that all women accept the screening 
tests and resulting treatment when administered. 
In addition, certain assumptions were made when using and adapting relevant data from 
secondary sources. Firstly, the effectiveness of GIFT was based on the sensitivity and 
specificity found in the biomarker validation study, as this has not been established in the 
field. The prevalence of diseases for the study population was based on the average estimates 
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from 11 studies conducted in South Africa from 2011-2018. These studies were all based in 
different study settings and included different age groups, although within the bounds of 15-
49 years, and they followed varying research methodologies. Furthermore, the probabilities 
of the four disease were averaged in order to create a simpler decision problem.  
Cost parameters were also collected from varying sources. A standard clinic visit was included 
for all model comparators, for which the costs were extracted from Kairu³³. Across non-GIFT 
strategies, this was then combined with cost estimates from other relevant sources. Cost 
sources for the different model comparators also differed in the extent to parameters were 
compounded. Laboratory testing, for example, was cost based on a single cost estimate 
received from the NHLS, while for Xpert and Microscope and GIFT unit costs were made 
available. Therefore, the costing of staff time and the inclusion of consumables were not 
standard across cost estimates. In accordance with Kairu³³, it was also assumed that screening 
with GIFT would have no additional personnel time implications, as it was regarded as 
insignificant.  
Sensitivity Analysis 
We performed one-way sensitivity analyses to establish the robustness of the results given 
the high variability of estimates found in literature, uncertainties in the data and the 
assumptions made in the model. Key parameters were varied across a reasonable range while 
holding all other parameters constant at their base case values. These parameters included 
GIFT test cost, personnel time, GeneXpert test costs, GIFT sensitivity, lost to follow-up rates, 
disease prevalence, test and treatment uptake and syndromic management sensitivity. 
Parameter values were varied based on relevant values from the literature. 
We also performed a threshold analysis for GIFT sensitivity. Lastly, four alternative decision 
trees in which the decision analysis was modelled for each disease separately was constructed 










Screening with GIFT-SM was the most cost-effective strategy in the base case scenario with 
an ICER of R38.20 (US$ 2.60) per women diagnosed and put on treatment. GIFT-Xpert-
Microscopy, with an ICER of R586.76, was dominated and thus eliminated from the decision-
making problem. The remaining two strategies were also cost-effective, but with much higher 
ICERs than GIFT-SM of R740.61 and R902.37 respectively.  
Table 4: Base case cost-effectiveness results 
Figure 2 provides a graphical depiction of the relationship between the incremental cost and 
effectiveness of each alternative and three hypothetical thresholds. All the ICERs appear in 
the first quadrant, revealing that each comparator presents a cost-effective option; being 
more both more effective and costly than its predecessor. The figure graphically shows that 
GIFT-SM is the most cost-effective of the three, having the lowest ICER. To make inference 
about the absolute cost-effectiveness of alternatives in the decision-making context, a cost-
effectiveness- or willingness-to-pay (WTP) threshold is required. For a threshold lower than 
R38,20 (USD 2.60), none of the options would be cost-effective. Similarly, for a threshold 
above R740.61 (USD 50.36), but below R902.37 (USD 61.36), both GIFT-SM and PCR-



















Management 193.17 -  0.11 -  -  
 
-  89,5% 4,0% 
GIFT-SM 218.57 25.40 0.77 0.67 38.20 2.60 23,0% 29,0% 
GIFT-Xpert-
Microscopy 580.66 387.49 0.77 0.66 586.76 ¥ - 23.0% 0.1% 
PCR-
Microscopy  707.90 514.73 0.80 0.70 740.61 50.36 20.0% - 
Xpert-
Microscopy 989.97 796.80 0.99 0.88 902.37 61.36 1,2% 0.5% 
*Cost per women to diagnose and treat a single episode of disease 
**Combined sensitivity of approach  





































There exists no standard threshold in South African but there have recently been attempts to 
estimate such thresholds. Woods et al.⁵⁰ estimated a cost-effective threshold of USD 1,175 – 
4,714 (in 2013 prices) per DALY averted, while Meyer-Rath et al.⁵¹ estimated a revealed WTP 
threshold of USD 547–872 per life year saved. However, the results of this study cannot be 
directly compared to these thresholds due to the lack of a mutual ICER comparator, and no 
definite conclusion on the absolute cost-effectiveness can thus be made. Nonetheless, an 
ICER of R38.20 (USD 2.60) per additional woman diagnosed and treated seems low in the 
South African context.  










Since screening with GIFT gives an indication of genital inflammation only, the exact infection 
would still not be identified, and treatment can thus not be made more specific to minimise 
overtreatment. The GIFT strategies, however, show improvement in terms of identifying 
cases that is typically missed under the current standard of care (23% compared to 89.5%), 
albeit not as effective as PCR, Xpert and Microscopy.  
Sensitivity Analysis  
The cost of the GIFT test assay was varied 50% both ways to account for possible fluctuations 
in the current quoted prices as manufacturing is still underway. This rendered similar ICERs 
than the base-case scenario with no changes in the relative cost-effectiveness observed.  
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The time cost of administering GIFT to a patient was not explicitly factored into the cost study 
by Kairu³³ since time spent on this additional aspect of the clinic visit was regarded negligible. 
However, it was estimated that this screening process would take up to 20 minutes per 
patient (33). To test the effect of this assumption on the results, the personnel cost related 
to the GIFT strategies was varied upward across a reasonable range. These variations revealed 
that GIFT-SM becomes less cost-effective with an increase in personnel cost but remained the 
most cost-effective strategy in the model.  
The cost of GeneXpert test assays was also varied with 50% both ways to account for 
exchange rate variability (upward) and the possibility that the GeneXpert machines can in 
some cases be provided to state institutions at subsidised prices (downward) (Gwen 
Stephens, Ceipheid, personal communication 2019, June 3). In this analysis, the relative cost-
effectiveness also remained unchanged with the upward variation, but Xpert-Microscopy 
dominating PCR-microscopy when the cost was varied downward. 
Since GIFT has not been validated in a pilot study, the base-case sensitivity of the device is 
based on the findings from the biomarkers study. Consequently, there exists a possibility that 
the device might have different sensitivity in practice. GIFT sensitivity was consequently 
decreased with 50% and increased to 100% to test this limitation. These variations did not 
affect relative cost-effectiveness of the comparators, although the ICER of GIFT-SM did 
increase with a decrease in sensitivity and vice versa.  
Disease probabilities and LTFU were varied according to the highest and lowest estimates 
found in the literature. At both 11% and 29% average disease probability, the ICERs of each 
model comparator did not change significantly from the base-case scenario and the cost-
effectiveness conclusions remained the same.  When the LTFU was varied to 49%, GIFT-Xpert-
Microscopy continued to be eliminated due to extended dominance. In addition, PCR-








Table 5: The impact of one-way sensitivity analyses on the cost-effectiveness results  
 
 





Base case 38.22  Dominated* 740.61  902.38  
COST PARAMETERS 
GIFT test assay 
    
+50% 41.79  Dominated* 740.61  902.38  
-50% 34.65  Dominated* 740.61  902.38  
GIFT personnel time 
    
+50% 161.30  Dominated* 740,61  902,38  
+30% 112,06  Dominated* 740.61  902.38  
+10% 62.83  Dominated* 740.61  902.38  
GeneXpert Test assays 
    
+50% 38.22  Dominated* 740.61  1 194.18  
-50% 38.22  Dominated* Dominated**  610.57  
PROBABILITIES 
GIFT sensitivity 
    
+27% 29.11  Dominated* 740.61  902.38  
-50% 86.98  Dominated* 740.61  902.38  
LTFU  
    
11% 38.22  Dominated* 655.84  902.38  
49% 38.22  Dominated* Dominated* 902.38  
Disease probabilities 
    
11% 37.45  Dominated* 740.10  901.86  




    
15% 40.99 Dominated* 791.89 950.83 
23% 47.07 Dominated* 903.03 1051.18 





58.8%*** 157.90  Dominated* 855.13  992.51  






18.9% 7.22 Dominated* 740,61  902,38  
25% 9.56 Dominated* 740,61  902,38  
50% 19.11 Dominated* 740.61  902.38  
70% 142.95 Dominated* 740.61  902.38  
*Eliminated through extended dominance 
** Eliminated through absolute dominance 
***Survey included both male and female school learners. 
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Our model assumed that all women who have symptoms seek care under syndromic 
management and that all women who are screened accept the test administered to them. 
These assumptions were tested based on other studies and estimates found in the literature. 
Health care-seeking behaviour among women in South Africa remains limited to an extent 
and is typically worse in rural compared to urban settings (35). Estimates from two sources 
were used to test the health care seeking assumptions with further one-way sensitivity 
analyses. Firstly, Sahin-Hodoglugil (2003)³⁴ produced a baseline estimate of 70% of women 
seeking care for STIs. Secondly, the National Survey on youth risk behaviour was utilised. This 
survey revealed that 58.8% of the study population received treatment for a known STI. These 
variations did not change the relative cost-effectiveness of any of the strategies and GIFT-
Xpert-Microscopy remained dominated. It did produce higher ICERs for the remaining 
strategies than in the base-case analysis, due to a decrease is the cost of the baseline strategy, 
syndromic management.  
The assumption on screening acceptability was tested by introducing this parameter to the 
model and varying it based on estimates used in two studies conducted in the United 
Kingdom, due to lack reliable local estimates available for this study setting. This analysis 
results in a paradox since lower acceptance rates increases the relative cost-effectiveness of, 
but in reality, fewer health outcomes would be realised if fewer women agree to be screened, 
as in these scenarios. This is due to the structure of the model and ICER calculations. Care 
should be judging these estimates. To optimise this screening strategy, acceptance rates 
should be established and considered. No changes were, however, observed in the relative 
cost-effectiveness conclusions.  
A single threshold analysis was also conducted on GIFT test sensitivity. Threshold analysis 
revealed that the GIFT+SM strategy would remain the most cost-effective unless the 
sensitivity of GIFT were to decrease to below 14.83%. The individual decision tree analyses 
revealed that GIFT-SM was still the most cost-effective strategies when looking at the diseases 
individually. For bacterial vaginosis, GIFT-Xpert-Microscopy is dominated by PCR-Microscopy 
with absolute dominance. For trichomoniasis, GIFT-Xpert-Microscopy was dominated by PCR-




Table 6: Results from separated decision trees 
BV Incremental Cost 
(2019 ZAR) 
Incremental effectiveness  ICER 
Syndromic management - - - 
GIFT-SM 27,76 0,67 41,43 
GIFT-Xpert-Microscopy 504,71 0,67 753,30* 
PCR-Microscopy  514,92 0,70 735,60 
Xpert-Microscopy 796,88 0,90 885,42 
CT Incremental Cost Incremental effectiveness  ICER 
Syndromic management - - - 
GIFT-SM 25,08 0,63 39,75 
GIFT-Xpert-Microscopy 370,14 0,63 586,59 
PCR-Microscopy  514,83 0,66 778,87 
Xpert-Microscopy 797,09 0,86 925,78 
NG Incremental Cost Incremental effectiveness  ICER 
Syndromic management - - - 
GIFT-SM 24,21 0,59 40,96 
GIFT-Xpert-Microscopy 325,70 0,59 551,11 
PCR-Microscopy  514,05 0,62 827,79 
Xpert-Microscopy 796,03 0,82 969,59 
TV Incremental Cost Incremental effectiveness  ICER 
Syndromic management - - - 
GIFT-SM 25,50 0,59 43,14 
GIFT-Xpert-Microscopy 348,87 0,56 619,36** 
PCR-Microscopy  514,50 0,62 828,50 
Xpert-Microscopy 796,35 0,79 1014,46 
*Eliminated through absolute dominance 
**Eliminated through extended dominance  
 
Discussion  
A significant proportion of women with STIs and/or BV remain untreated under syndromic 
management due to the asymptomatic nature of their infections. In our model, we compared 
the cost and effectiveness of four alternative STI and BV management strategies to this 
standard of care. These strategies were modelled for women aged 15-49 years.  
The results from the economic evaluation suggest that the introduction of screening with the 
rapid GIFT device into the South African public health sector would be the most cost-effective 
way to improve care in this population and reduce the burden of STIs and BV, relative to other 
model comparators.  Given the interaction with HIV/AIDS, reducing this burden can 
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significantly reduce the amount of new HIV transmission and infections. Introducing this 
screening approach can also aid in the identification of high-risk women to be put on pre-
exposure prophylaxis programs for the prevention of HIV (Masson and Passmore, Personal 
Communication, 2018, November 18). According to Sahin-Hodoglugil et al.³¹, the early 
treatment and prevention of curable STIs such as chlamydia and gonorrhoea can lead to 
significant health gains in a population. 
The robustness of the cost-effectiveness results was tested in various sensitivity analyses. The 
conclusion remained the same in all the analyses with the ICER of GIFT-SM only increasing or 
decreasing and PCR-Microscopy eliminated by dominance in two cases. From the sensitivity 
analysis, testing the acceptance of GIFT screening by women arises as an opportunity for 
further study during the GIFT pilot study or other research in order to truly establish whether 
the approach could improve STI management or not.  
Given that GIFT-SM does not render desirable health outcome in terms of overtreatment, 
PCR-Microscopy might be considered in high-risk of high-burdened settings to enhance STI 
management in such settings. However, although GIFT-SM is the least desirable in terms of 
overtreatment (see table 5), Lennard et al.⁴⁷ and Passmore, Jaspan and Masson³⁰ note that 
the other infections present in women that typically lead to a false positive resu lt with GIFT, 
such as Atopobuim, Prevotella, Shuttleworthia and Aerococcus, are not detected by gold 
standard STI and BV tests. These organisms would, however, also respond to the antibiotics 
administered. This would result in unintended health gains not measured in this analysis. 
However, Kairu³³ found that from a budget impact perspective the national roll-out of an 
annual, opportunistic screening intervention might not be feasible. Such an approach would 
provide a single GIFT screening to every woman, between the ages of 15 to 45 years, at a 
primary care health care facility, annually. Requiring up to 17% of the available budget for 
HIV/AIDS intervention, it is not likely to be prioritised amidst the array of existing and other 
new interventions. Nevertheless, tailor-made implementation strategies could be considered, 
such as implementing screening only in high-burdened or high-risk populations, to optimise 
the introduction of screening amidst the resource constraints faced by the Department of 
Health.  Such strategies should be further researched for sound policy recommendations to 
be made.  
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To limit start-up costs, GIFT screening could be introduced alongside annual HIV testing 
programmes. The latter is a key objective of South Africa’s National Strategic Plan for HIV, TB 
and STIs 2017-2020 (28). Alternatively, key populations should be identified for whom the 
approach should be initiated. Such populations could include women at high risk for STIs such 
as sex workers, HIV-positive persons, young adults or women residing in settings with known 
high disease prevalence. In this case, register-based screening (target individuals are 
identified through existing databases) could be useful or key screening questions could be set 
up to identify these individuals as they enter healthcare (opportunistic screening). 
Information system challenges might arise, however, and additional costs might arise where 
systems would need to be created or improved to ensure adequate record-keeping of 
screening history or to identify high-risk individuals.  
The study faced various challenges and limitations, with the simplicity of the model of choice 
due to data constraints and the use of secondary data from varying sources likely being the 
most significant. The model was designed as a static, decision tree analysis that did not 
include any sequelae or long-term complications typically associated with STIs nor did we 
factor in re-infections. This might likely have led to the cost of having an STI or BV being 
underestimated. Adverse drug events were also not included due to the short-term nature of 
the analysis and would likely have underestimated the cost of treatment. On the contrary, 
the model did not include the potential benefits of HIV/AIDS prevention through STI 
treatment or the effect of increased diagnosis and treatment on STI prevalence in the 
population over time. This may have led to an underestimation of effectiveness of the 
screening interventions. To establish a more sophisticated, dynamic model that would be able 
to inform decision-making more comprehensively, future research should focus on estimating 
these parameters.  
Furthermore, the effectiveness of GIFT was assumed to be the sensitivity and specificity found 
in a biomarker validation study and is potentially thus not a true representation of the 
effectiveness that would be yielded when implemented in the field. Although this assumption 
was tested in the sensitivity analysis, implementation challenges that may arise in the field 





Although syndromic management remains the most affordable approach to care, it is not 
adequately dealing with the massive STI and disease burden faced women South African 
women. Screening with gold standard and more rapid tests such as GeneXpert and 
microscopy, on the other hand, provides more desirable health outcomes in terms of women 
diagnosed and treated and limiting overtreatment, but it remains relatively expensive in this 
resource-constrained setting. The results from the economic evaluation suggest that the 
introduction of screening with the rapid GIFT device in the South African public health sector 
would be the most cost-effective way to improve STIs and BV care in women while 
simultaneously having positive effects on the HIV-epidemic. However, previous research 
suggests that national implementation may not be affordable within the South African 
context. This analysis presents a first attempt to establishing the cost-effectiveness of the 
various screening. It reveals that further research should be done on the feasibility of different 
implementation options within this resource-constrained setting. Furthermore, to enable the 
establishment of a more comprehensive and dynamic model research should focus on 
quantifying the effect screening for STIs would have on prevented HIV cases and STI disease 
probability and its consequent impact on the outcomes of the decision model.   
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SEXUALLY TRANSMITTED INFECTIONS AND BACTERIAL VAGINOSIS IN SOUTH 
AFRICA 
South Africa houses one of the largest burdens of sexually transmitted infections 
(STIs) and bacterial vaginosis (BV) in the world (1). Coupled with the widespread HIV 
epidemic, the country faces a significant public health challenge (2). This double 
burden of disease disproportionately affects the female population. It is estimated 
that at least 25% of South African women are infected with a bacterial STI and 
women are up to eight times more likely to acquire HIV than men (3,4). The 
majority of STI and BV cases in women do not, however, have any recognisable 
symptoms and consequently do not seek care (5). Failure to treat, or delaying 
treatment of STIs and BV can lead to various sexual and reproductive health 
complications and can facilitate the acquisition and transmission of HIV (6).  
The public health system serves around 84% of the population, therefore the vast 
majority of this burden rests on Department of Health resources (7). In this system, 
most STIs are managed syndromically, rather than with resource-intensive 
etiological diagnosis. Under this approach developed and endorsed by the World 
Health Organization (WHO) for resource-constrained settings, syndromes of a 
specific STI or BV are identified according to pre-identified groups of signs and 
symptoms. Patients are then provided with treatment that will address the 
majority, or the most serious, of organisms typically associated with the identified 
syndrome (8).  
Gold standard diagnostic tests for STIs and BV remain expensive in the South African 
context. Strides have, however, been made in the development of more rapid, 
point-of-care (POC) tests using the same technology as laboratory-based gold 
standard tests. Tests such as Cepheid’s GeneXpert test assays for different STIs have 
been developed and are commercially available in South Africa. These tests are 
ideally performed in the health care facility and can present results in roughly 90 
minutes (9,10). Researchers at the Division of Medical Virology at the University of 
Cape Town recently developed another rapid POC; GIFT (Genital Inflammation 
Test). GIFT is a relatively inexpensive, cytokine rapid test that detects inflammatory 
bacteria in the female genital tract. STIs and BV cause genital inflammation, 
regardless of other symptoms such as vaginal discharge or genital ulcers being 
present. The measurement of key inflammatory cytokine biomarkers with a rapid 
POC test can thus potentially identify asymptomatic cases that are otherwise missed and consequently, women who 
are at an increased risk of acquiring and transmitting HIV (Masson and Passmore, Personal Communication, 2018, 
November 18).  This study follows a cost estimation and budget impact analysis conducted by Kairu¹¹ which found 
that national implementation of GIFT screening would require up to 17% of the available budget for HIV/AIDS, 
suggesting that it would be unaffordable under the current budget.  
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• The co-burden of STIs 
and HIV remains a large 
burden on the South 
African public health 
system and women are 
disproportionately 
affected.  
• Many STI and BV cases 
are missed under the 
current standard of care. 
• Screening women at 
primary health care level 
can improve the 
management of female 
sexual and reproductive 
health.  
• GIFT provides a possible 
solution to diagnose and 
treat significantly more 
women at a reasonable 
extra cost of R38.22 per 
additional diagnosed 
and treated women.  
• Given that national 
rollout is unaffordable 
under the current health 
care budget, different 
implementation 




DESCRIPTION OF STUDY 
The study was conducted to establish whether screening with the newly 
developed GIFT device would be a cost-effective approach to STI and BV 
management for women in the reproductive age from the viewpoint of the South 
African Department of Health.  A cost-effectiveness study, in the form of a 
decision tree analysis, was conducted from the perspective of the Department of 
Health the provider of health services. Five different screening and diagnostic 
approaches were modelled for detecting BV, chlamydia, gonorrhoea and 
trichomoniasis women in the reproductive age (15-45 years).  
Screening Strategies 
6. Syndromic management of symptomatic women seeking healthcare  
7. Screening all women entering primary care facilities with GIFT followed 
by syndromic management for GIFT-positive cases  
8. Screening with GIFT followed by testing with GeneXpert NG/CT and 
GeneXpert TV assays and microscopy for GIFT-positive cases  
9. Screening with GeneXpert (NG/CT and TV) and microscopy alone  
10. Screening with gold standard laboratory testing  
(NG = Neisseria gonorrhoea; CT = Chlamydia trichomonas) 
To establish the relative cost-effectiveness of these five strategies, the 
incremental cost-effectiveness ratio (ICER) was obtained for each. This was 
measured as the additional cost incurred per women diagnosed and treated for 
BV, chlamydia, gonorrhoea and trichomoniasis.   
Relevant cost and effectiveness data, as well as the probability of model events, 
were obtained from various published and unpublished sources. Cost estimates 
included all clinic-level capital and recurrent costs associated with each strategy 
for diagnosing and treating a single episode of disease. Effectiveness was based 
on the relative sensitivity and specificity measures of the diagnostic test(s) or 
clinical approach.  
KEY FINDINGS 
Although syndromic management remains the least expensive approach to STI 
management, it leaves many STI and BV cases (up to 89.5%) (12) undiagnosed 
due to the high number of asymptomatic infections in women. Nevertheless, 
expensive gold standard etiological diagnosis in off-site laboratories remains 
unfeasible in the South African context due to resource-constraints.  
The results from the analysis revealed that screening with GIFT and following 
with syndromic management-based treatment for positive cases was the most 
cost-effective approach in the model. It rendered an ICER of R38.22 per women diagnosed and treated. GIFT 
followed by GeneXpert and microscopy was dominated by GeneXpert and microscopy alone. Strategies 4 and 5 
rendered ICERs between of R740.61 and R902.38 respectively. 
Screening women at primary health care level can thus improve the management of female sexual and reproductive 
health by identifying asymptomatic cases. At a relatively low additional cost per women, much greater health gains 
can be made in the management of STIs and BV in women, in comparison to the standard of care. It can also aid in 
the prevention of HIV, not just by diminishing opportunities for STI- or BV-associated transmission and acquisition, 
but also by identifying women to be placed on pre-exposure prophylactic drugs. Such screening can also assist with 




Bacterial Vaginosis: Vaginal  
disorder characterised by the 
depletion of hydrogen peroxide 
producing lactobacilli in the vaginal 
tract caused by an  imbalance in the 
ecology of normal vaginal flora. 
Cytokines: Proteins secreted by 
cells of the immune system that 
affect communication and 
interaction between cells. To 
regulate the bodies response to 
trauma or disease. Inflammatory 
cytokines promote infection.  
Cost-effectiveness: When the 
benefits of an intervention is worth 
at least what is paid for them. 
ICER: The ratio of incremental cost 
to incremental effectiveness of 
interventions considered in the 
model. Commonly expressed as the 
additional cost per each additional 
effect derived from an intervention, 
in comparison to the standard of 
care. 
Dominated strategy: an alternative 
which renders higher incremental 
cost but lower effectiveness than 
previous less costly strategy or 
which delivers an ICER higher than 
the next more costly strategy.  
Opportunistic vs. register-based 
screening: Opportunistic screening 
refers to annual otherwise periodic 
screening provided during non-STI 
related healthcare visits. Register-
based screening involves 
individuals being contacted and 
invited for testing based on 




POLICY IMPLICATIONS AND RECOMMENDATIONS 
• Current syndromic management guidelines are not effective in handling the massive burden of disease faced 
women South African women.  
• Introduction universal opportunistic annual screening for all women between the ages of 15 and 45 years 
entering primary health care clinics could improve health outcomes but is not affordable given current 
budget constraints.   
• Focused implementation strategies could be considered, such as introducing the intervention in high-risk 
population. Such populations could include women at high risk for STIs such as sex workers, HIV-positive 
persons, young adults or women residing in settings with known high disease prevalence. This would require 
register-based screening to identify individuals based on medical history or presenting key screening 
questions to identify individuals as they enter healthcare (opportunistic). 
• To ensure optimal coverage of the target population, sound information systems would need to be in place 
to ensure adequate record-keeping of screening history and to identify high-risk individuals in the case of 
register-based screening.  
• Efforts should be taken to establish the acceptability of screening in the target population, before 
implementation. The GIFT pilot study could be an opportunity for such research.  
CONCLUSION 
The South African public sector succumbs to the combined burden of curable STIs, BV and HIV which 
disproportionately affects the female population. The newly developed rapid POC, GIFT, provides a promising tool 
with which to improve STI and BV management at primary care level. The results from this study indicate that 
implementing screening with GIFT could be a cost-effective option for the Department of Health to diagnose many 
cases which would typically be missed under the syndromic management due to their asymptomatic nature. 
Implementing a universal, annual GIFT screening for all women entering primary health care in the public sector 
would significantly improve detection and treatment of STIs and BV. However, the feasibility of this remains doubtful 
within the constrained health budget . Alternative strategies, such as screening high-risk women only, could be 
considered. Further research is required to supplement decision-making.   
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